Latest / Cult of Conspiracy / Deplorable Cult Nation: mRNA Flu Vaccine with Nurse Nicole
Transcript
- 0:00Speaker 1: They sold me cum in a clean white room.
- 0:03Speaker 2: A stack of foams in a polished tomb.
- 0:08Speaker 1: Smiles too fast, hands too sure.
- 0:14Speaker 2: I smell the smoke behind the cure. I read the
- 0:24Speaker 2: fine print, saw the cracks. Every promise came.
- 0:46Speaker 1: Hi and welcome back to another episode of Deplorable Nation.
- 0:49Speaker 1: I'm your host, Deplorable Janet. And today, ladies and gentlemen,
- 0:54Speaker 1: back with me is the most amazing, beautiful soul on
- 1:00Speaker 1: the planet, the lovely Nurse Nicole. How are you, my
- 1:03Speaker 1: beautiful friend?
- 1:05Speaker 2: Oh my goodness, such a great intro as usual. I'm
- 1:08Speaker 2: doing very well. Excited about this topic today. This is
- 1:11Speaker 2: going to be one of those ones that people are
- 1:13Speaker 2: going to have so many questions on, especially those of
- 1:16Speaker 2: us in healthcare. But yeah, how are you doing?
- 1:20Speaker 1: Fabulous. Fabulously lovely, my dear. And I will say, there
- 1:25Speaker 1: will be people with questions, but there's also going to
- 1:28Speaker 1: be people that are like, ah, God, I don't want
- 1:30Speaker 1: to hear anything about it.
- 1:31Speaker 2: Right. Right. We say bring it on. Bring it on.
- 1:35Speaker 1: It's okay. That's all right. Not everybody's meant to love us.
- 1:39Speaker 1: We love us. So that's all that matters. Just saying.
- 1:44Speaker 1: So today, ladies and gentlemen, we are going to be
- 1:48Speaker 1: going down the rabbit hole of the brand new... August
- 1:53Speaker 1: the 5th, 2026, just approved mRNA flu vaccine. And we're
- 1:59Speaker 1: going to tell you all the deets that you need
- 2:01Speaker 1: to know, go over some studies that may shock you,
- 2:06Speaker 1: and even some things from the FDA that we're like, hmm,
- 2:11Speaker 1: not too sure about this. Anyways, yeah, it's going to
- 2:16Speaker 1: be an interesting topic of conversation. Some people I know
- 2:21Speaker 1: are going to just like tune out, but this is important.
- 2:27Speaker 1: And I will say, even though it was approved, it
- 2:32Speaker 1: is not rolling out right now for people to take.
- 2:37Speaker 1: I did extensive research on that. So the flu vaccines
- 2:44Speaker 1: that we already have are going to be in place
- 2:48Speaker 1: for the 2025 season. the flu vaccines that we had
- 2:57Speaker 1: in the 2025 initiative are going to be the same ones.
- 3:03Speaker 1: They're not going to roll this out until next year.
- 3:08Speaker 1: So after flu season, so next flu season is when
- 3:14Speaker 1: they are supposedly going to roll this out. But There
- 3:19Speaker 1: were a lot of reasons why. And the federal government
- 3:23Speaker 1: themselves and the FDA said that due to legal and
- 3:29Speaker 1: regulatory concerns, we are going to stick with 2025 recommendations. Now,
- 3:38Speaker 1: if the FDA is telling you that there's legal concerns
- 3:42Speaker 1: with this, you best pay attention.
- 3:46Speaker 2: Right. That's a big deal. I mean, to admit that
- 3:48Speaker 2: is a huge, huge ordeal. So good to see that
- 3:52Speaker 2: there's some integrity possibly still left in the three little agencies,
- 3:57Speaker 2: excuse me.
- 3:57Speaker 1: A little sliver anyway, right?
- 3:59Speaker 2: Sliver, yeah.
- 4:01Speaker 1: So here's the questions that are remaining important regarding this.
- 4:09Speaker 1: Long-term safety studies, the rare adverse events, repeated annual exposure,
- 4:16Speaker 1: and whether it actually provides superior clinical benefits to the
- 4:22Speaker 1: preferred vaccines in adults that are 65 and older. Because
- 4:27Speaker 1: this actual vaccine, it's from Moderna, and it's called mFluciva,
- 4:35Speaker 1: or mRNA 1010. And it's currently approved for adults 50
- 4:42Speaker 1: and older with, expedited use in adults 65 and older.
- 4:52Speaker 1: So they would like to really push this for the
- 4:57Speaker 1: 65 and older group right now. However, safety studies on this,
- 5:05Speaker 1: and these are going to be post-market research, so it
- 5:09Speaker 1: comes out on the market, and then they have until
- 5:12Speaker 1: 2030 to see if this actually does what they're claiming
- 5:20Speaker 1: that it does.
- 5:23Speaker 2: Yeah, that's interesting considering the flu vaccine notoriously has very
- 5:28Speaker 2: low efficacy.
- 5:29Speaker 1: Which is a big.
- 5:32Speaker 2: Concern that we have in healthcare as it's pushed heavily
- 5:36Speaker 2: on healthcare workers, first responders, and then the specific vulnerable
- 5:41Speaker 2: populations as I'm using air quotes. So I think it's
- 5:45Speaker 2: very telling and very interesting that they're making it a
- 5:48Speaker 2: point to tell the public that they're really looking at
- 5:51Speaker 2: the ages 50 years and older when this is notoriously
- 5:57Speaker 2: pushed out into all populations younger than 50. Factually. which
- 6:02Speaker 2: is very, very much a concern that we continue to
- 6:05Speaker 2: have and why with the low efficacy, meaning for those
- 6:08Speaker 2: that may not understand, it really just does not work.
- 6:11Speaker 2: The strains that usually are chosen for the flu vaccine
- 6:15Speaker 2: do not usually align with the actual viral viruses that
- 6:19Speaker 2: they are targeting for that year, which is a huge,
- 6:22Speaker 2: huge concern that you're injecting something that you're told should
- 6:25Speaker 2: be able to help. And so, but I think, you know,
- 6:28Speaker 2: before we really dive into it, it's really important to
- 6:30Speaker 2: note that the age group that they're making this, you know, Oh,
- 6:33Speaker 2: don't worry. Like only ages 50 years and up when
- 6:36Speaker 2: technically when it rolls out, they start pushing it on
- 6:39Speaker 2: much younger population.
- 6:41Speaker 1: And then, and then they're probably going to include kids
- 6:44Speaker 1: and infants and, and whatever with this, even though post-marketing
- 6:50Speaker 1: research is not required to be done until 2030. Again,
- 6:56Speaker 1: that's an important caveat because, Because of all these questions
- 7:00Speaker 1: that I just read that are still like up in
- 7:02Speaker 1: the air. So take this, but we don't know if
- 7:07Speaker 1: it's going to cause death or debilitating injury or, you know,
- 7:12Speaker 1: all of these things we won't know until 2030, but
- 7:16Speaker 1: go ahead and take it. Uh, it's like a crapshoot, right?
- 7:22Speaker 2: Right. Russian roulette.
- 7:24Speaker 1: So, um, This is not the traditional vaccine, of course,
- 7:29Speaker 1: since this is an MRI. Oh, my word. mRNA vaccine. Sorry,
- 7:37Speaker 1: I can't talk today. I'm tongue-tied. It deals with your
- 7:42Speaker 1: messenger RNA, and what it does, it instructs your cells
- 7:47Speaker 1: to produce influenza hemagglutinin, which... It's a protein that's found
- 7:56Speaker 1: on the surface of the influenza virus as well as
- 8:01Speaker 1: other viruses. Could this also be lumped into COVID? Since
- 8:08Speaker 1: they're very closely related. Not sure. And so it tells
- 8:14Speaker 1: the cells to produce this hemagglutinin to... Combat, whatever. And
- 8:21Speaker 1: the reason why hemagglutinin got its name is because red
- 8:26Speaker 1: blood cells can actually become linked together like a chain
- 8:32Speaker 1: because this mRNA binds to receptors on multiple red blood
- 8:41Speaker 1: cells at a time. So it can cause like a
- 8:44Speaker 1: chain link effect. And they're thinking that this is a
- 8:48Speaker 1: good thing. I already see warning flags from that just
- 8:51Speaker 1: saying because how do you think clots form when red
- 8:54Speaker 1: blood cells get stuck together? So anyway, that's what it's
- 9:01Speaker 1: supposed to do. So it's going to supposedly works in
- 9:07Speaker 1: a different platform than what traditional flu vaccines work. But again,
- 9:12Speaker 1: we don't really know if it really does work because... 2030.
- 9:18Speaker 1: So why are they using this platform for influenza? And
- 9:26Speaker 1: have we used this before? Why?
- 9:27Speaker 2: Yes.
- 9:28Speaker 1: Yes, we have with COVID and we see all of
- 9:31Speaker 1: the issues and the problems and the nanoparticles and stuff
- 9:37Speaker 1: like that. And they have to use nanoparticles for this
- 9:43Speaker 1: because they It immediately starts to break down. And the
- 9:49Speaker 1: regular vaccine does. And so nanoparticles keep it wrapped in
- 9:55Speaker 1: these lipids. It's like encapsulated. And who knows? what the
- 10:01Speaker 1: hell happens from there because we've seen that with the
- 10:04Speaker 1: Pfizer and they wanted 75 years to cover up their studies,
- 10:11Speaker 1: post-marketing research.
- 10:13Speaker 3: Right.
- 10:13Speaker 2: And what we do know with mRNA technology, because those
- 10:17Speaker 2: records are, were not able to be sealed for 75 years.
- 10:20Speaker 2: They had to go out and put it on record.
- 10:23Speaker 2: And it came out into their package inserts, the manufacturer
- 10:27Speaker 2: inserts that, you know, we do know with the mRNA
- 10:30Speaker 2: technology that for quite a few people, it causes these
- 10:33Speaker 2: cytokine storms. It causes this, you know, systemic inflammation. It
- 10:38Speaker 2: causes micro clotting. It causes the body to have a
- 10:42Speaker 2: higher chance to form clots and which is why we
- 10:46Speaker 2: saw and continue to see a rise in heart attacks
- 10:49Speaker 2: and strokes and neurological issues. And so, you know, even
- 10:53Speaker 2: though we still don't have a lot of long-term studies
- 10:57Speaker 2: on the mRNA, despite what some may say, we do
- 11:01Speaker 2: see what that version of the mRNA and the COVID
- 11:06Speaker 2: vaccines have caused harm and death. And so this is
- 11:09Speaker 2: why the public, rightfully so, is outraged and a little
- 11:16Speaker 2: concerned to know that mRNA is now going to be
- 11:19Speaker 2: pushed on a flu vaccine, which again is pretty much
- 11:24Speaker 2: pushed across the board. And as you mentioned, even though
- 11:27Speaker 2: it says ages 50 and up, flu vaccines are on
- 11:31Speaker 2: the schedule for infants. And so these are very valid
- 11:36Speaker 2: concerns because of how mRNA has panned out since we've
- 11:41Speaker 2: seen it with the COVID-19 vaccines since the pandemic.
- 11:44Speaker 1: Well, and let's talk about what is the science behind
- 11:49Speaker 1: or what could possibly be causing the cardiac issues and stuff,
- 11:56Speaker 1: given that they're using lipid, which is cholesterol, people. lipid
- 12:02Speaker 1: nanoparticles to wrap these in? What could be causing cardiac
- 12:07Speaker 1: events and clots and everything else?
- 12:12Speaker 2: Well, are you meaning because of the actual way that
- 12:15Speaker 2: the blood is sticking with the micro clotting, how it's
- 12:18Speaker 2: throwing out the clots? I mean, the vaccine injured that
- 12:21Speaker 2: I've worked with consistently have across the board some sort
- 12:25Speaker 2: of micro clotting disorder. And so it's usually something that
- 12:29Speaker 2: we see more in females, although men can have it too,
- 12:33Speaker 2: but it also shows in these autoimmune flares where maybe
- 12:36Speaker 2: some of these autoimmune issues were dormant. And, you know,
- 12:39Speaker 2: now this COVID-19 vaccine has, you know, basically broken it
- 12:43Speaker 2: open and brought it to the forefront. And so for,
- 12:47Speaker 2: for the actual lipid, you know, wrapping itself around, this
- 12:50Speaker 2: is where the spike protein is entering in the cell.
- 12:54Speaker 2: And it's replicating. And that replication is causing these cells
- 12:59Speaker 2: to become sick and damaged. And, you know, like I said,
- 13:03Speaker 2: in a fair amount of people, causing them to form
- 13:05Speaker 2: these clots or have clot showers where they're just starting
- 13:10Speaker 2: to basically throw all of these blood clots in various
- 13:13Speaker 2: different scenarios. And sometimes it can happen shortly after the vaccine.
- 13:17Speaker 2: Sometimes it's something that develops with time and turns into
- 13:20Speaker 2: another health condition. And then those health conditions further decline
- 13:25Speaker 2: because the vaccine injured aren't recognized as vaccine injuries. So
- 13:28Speaker 2: they don't get really the help that they need. So
- 13:31Speaker 2: this is why it's such a concern because the mRNA
- 13:33Speaker 2: technology is not going to just stay in vaccines. They're
- 13:37Speaker 2: trying to look at putting it into our food and
- 13:39Speaker 2: other sources. So, you know, with what we continue to
- 13:44Speaker 2: see with that lipid nanoparticle and how it's, again, wrapping
- 13:49Speaker 2: itself around the cell, a lot of people think that
- 13:52Speaker 2: this is something that you can get rid of. I
- 13:55Speaker 2: have not really seen a successful case of the spike
- 13:58Speaker 2: protein being removed entirely. And so it continues to replicate
- 14:04Speaker 2: itself and cause all these health issues. And so I
- 14:08Speaker 2: know it was kind of a long answer, but essentially
- 14:10Speaker 2: it's just, it's by design. It's a bioweapon that is
- 14:14Speaker 2: built to take over these healthy cells, replicate itself, And
- 14:19Speaker 2: then it can turn into, again, all these issues with
- 14:22Speaker 2: this micro clotting. And that's how you end up getting
- 14:24Speaker 2: these heart attacks and strokes and other neurological issues, vision
- 14:29Speaker 2: problems because clots are forming behind the eyes, etc. So
- 14:32Speaker 2: it's tragic. And, you know, they said it wasn't going
- 14:35Speaker 2: to go outside of the injection site. which is false.
- 14:39Speaker 2: We know that it crosses blood-brain barrier, breast milk, placenta.
- 14:44Speaker 2: It's going in every vital organ. And so once it starts,
- 14:48Speaker 2: once it's injected, it doesn't stop. And one of the
- 14:52Speaker 2: things that Dr. Peter McCullough had mentioned in a previous
- 14:56Speaker 2: interview was, how long does the spike continue to reproduce?
- 15:02Speaker 2: And for some people, it may not. Again, virus spike
- 15:06Speaker 2: versus the injectable spike is two different things. However, there's
- 15:11Speaker 2: people that I know that haven't had a vaccine since
- 15:14Speaker 2: 2021 who are consistently producing spike and they're consistently sick
- 15:18Speaker 2: and have those autoimmune flares and issues and they need
- 15:21Speaker 2: the IVIG and they're constantly looking for treatment. So that's
- 15:25Speaker 2: the concern because there was no long-term testing. They are
- 15:28Speaker 2: essentially kind of the long-term study. Right.
- 15:32Speaker 1: They're the post-marketing study. Right.
- 15:35Speaker 2: And, you know, they're not getting helped. And so when
- 15:38Speaker 2: you are supposed to have no spike in your body
- 15:41Speaker 2: and then you go get a spike antigen or antibody test,
- 15:44Speaker 2: excuse me, and you're still showing critical results, that's concerning
- 15:50Speaker 2: because the physicians don't know how to stop it. And
- 15:53Speaker 2: that's why the mRNA technology is very concerning because there
- 15:56Speaker 2: is no real handle on it. to control what it's
- 16:00Speaker 2: doing internally in someone's body and how it takes over systemically.
- 16:05Speaker 1: Which is highly concerning that they've rolled out the flu vaccine.
- 16:11Speaker 1: And then I've heard that they're working on mRNA technology
- 16:18Speaker 1: for all of the vaccines that are on the childhood
- 16:21Speaker 1: schedule already. And if we already have that big a
- 16:26Speaker 1: problem with the spike, from COVID and then most people
- 16:31Speaker 1: during cold and flu season that are avid flu vaccine connoisseurs,
- 16:38Speaker 1: they will get a COVID vaccine. They will get a
- 16:41Speaker 1: flu vaccine. They'll get a pneumococcal vaccine. And then what
- 16:46Speaker 1: happens when you compound the problems with the spike from
- 16:51Speaker 1: the COVID vaccine with this. Is that going to duplicate
- 16:58Speaker 1: the problem?
- 17:00Speaker 2: I 100% think so, because they say, or they have
- 17:04Speaker 2: said in the past, and don't quote me on the specifics,
- 17:06Speaker 2: that for every mRNA COVID-19 vaccine you receive, because of
- 17:10Speaker 2: the mRNA portion, technically, each vaccine they projected would be
- 17:16Speaker 2: completely out of your system for most cases, a little
- 17:20Speaker 2: over a year and a half. Well, we realized that
- 17:22Speaker 2: not everybody, even if they got one, some of that
- 17:26Speaker 2: ended up fatal. And so, again, I know we're talking
- 17:29Speaker 2: about the flu vaccine, but the issue is the mRNA.
- 17:31Speaker 2: And a lot of people want to know why are
- 17:33Speaker 2: they leaning towards the mRNA? What is it about the
- 17:37Speaker 2: mRNA that we need to make these changes for? Like,
- 17:40Speaker 2: why are we doing that? And essentially, they say that
- 17:43Speaker 2: the mRNA technology benefits, you know, rapid production, which we
- 17:49Speaker 2: just talked about. Right. it does rapidly produce, that it's
- 17:54Speaker 2: highly safe, which.
- 17:57Speaker 3: Is to be discussed, and easy to fight new viruses
- 18:03Speaker 3: and diseases, which I find interesting because how many people
- 18:08Speaker 3: that got the mRNA technology with COVID and were told
- 18:11Speaker 3: that it's not going to.
- 18:15Speaker 2: Transmit amongst each other, that you would obviously be protected,
- 18:20Speaker 2: How many people got it and were not protected? How
- 18:23Speaker 2: many people still got COVID? How many people still got sick?
- 18:26Speaker 2: So this is why the public is not trustworthy of
- 18:31Speaker 2: mRNA technology because so far it's not been proven safe
- 18:35Speaker 2: for everybody. It is rapidly producing and they can't figure
- 18:38Speaker 2: out how to stop it because that's by design. It's
- 18:40Speaker 2: to continue to rapidly produce. And then they say it's
- 18:43Speaker 2: supposed to help treat and prevent viruses and disease, but
- 18:47Speaker 2: it's it doesn't stop transmission and people still got sick.
- 18:51Speaker 2: So all the things that they're saying that you could
- 18:53Speaker 2: do a simple Google search on why mRNA technology is
- 18:57Speaker 2: considered good has proven to not exist and still cause problems.
- 19:04Speaker 1: And, and I have a problem with that because why
- 19:07Speaker 1: they say they need this technology instead of the old
- 19:10Speaker 1: technology is because supposedly influenza viruses mutate quickly. Um, Hence
- 19:20Speaker 1: the multiple different strains and whatever. And like you mentioned earlier,
- 19:24Speaker 1: every year and months and months before flu season, they
- 19:30Speaker 1: will have to guesstimate which strains of the flu that
- 19:35Speaker 1: they think are going to be coming through. And this
- 19:38Speaker 1: is what we'll vaccinate against. So people, number one, who
- 19:44Speaker 1: got the old time vaccinations, either they got influence. immediately
- 19:52Speaker 1: after getting the vaccine. And so is that because they
- 19:58Speaker 1: got a different strand? Is it because they were using
- 20:03Speaker 1: live attenuated?
- 20:04Speaker 2: What?
- 20:07Speaker 1: Was the cause. We don't know, but that's why they say, Oh,
- 20:10Speaker 1: this technology is better because we don't have to guess
- 20:15Speaker 1: ahead of time. Cause this vaccine supposed to cover, what
- 20:19Speaker 1: is it like ABC and Victorian something? I don't know,
- 20:24Speaker 1: whatever all these strands are. But supposedly this is supposed
- 20:29Speaker 1: to cover all of them. However, in their own clinical trial,
- 20:37Speaker 1: They were using a regular strength old time flu vaccine
- 20:44Speaker 1: in their trial versus the mRNA stuff. Now, here's a
- 20:49Speaker 1: problem with that. There are different strengths of flu vaccine,
- 20:55Speaker 1: which most people probably have no clue. You're not aware
- 20:59Speaker 1: of this. So in the. more vulnerable, older populations, you're
- 21:06Speaker 1: supposed to be using a stronger vaccine for the flu.
- 21:13Speaker 1: In their own study that Moderna did, and the FDA
- 21:17Speaker 1: was like, your study parameters are wrong because that's not good.
- 21:24Speaker 1: They were using a regular, smaller dose, smaller strength, flu
- 21:32Speaker 1: vaccine in this population of people trying to prove it.
- 21:38Speaker 1: And so the first time that they sent certification paperwork
- 21:43Speaker 1: into the FDA, the FDA was like, you know what?
- 21:47Speaker 1: We got some questions on this because your study parameters
- 21:52Speaker 1: are wrong. You shouldn't be using this vaccine, blah, blah, blah.
- 21:56Speaker 1: But If you already have study parameters set, you can't
- 22:00Speaker 1: change it in the middle because it invalidates your study. Well,
- 22:05Speaker 1: guess what happened? They did change it. It didn't invalidate
- 22:10Speaker 1: their study according to the FDA. And the second time
- 22:13Speaker 1: they submitted it, the FDA was like, well, we know
- 22:17Speaker 1: there's all these problems, but okay, we're going to do
- 22:19Speaker 1: it anyway. Go ahead and approve it.
- 22:23Speaker 2: Which to me is unethical.
- 22:25Speaker 1: It is very unethical. It's like having like they did
- 22:28Speaker 1: with the COVID where they had that big study and
- 22:32Speaker 1: then they had no control group and study at all,
- 22:38Speaker 1: which totally invalidates your study.
- 22:41Speaker 2: Correct.
- 22:41Speaker 1: Like completely. You can't do that. And, and again, that
- 22:45Speaker 1: was submitted to the FDA under the COVID stuff. And
- 22:49Speaker 1: it still got approved, even though the study is invalidated
- 22:53Speaker 1: because you can't do those things. You have strict guidelines
- 22:58Speaker 1: that you have to follow when you're doing a clinical study.
- 23:02Speaker 1: And so there's massive problems with the COVID and this
- 23:07Speaker 1: from the get go. And the FDA knows there's problems
- 23:10Speaker 1: and they went ahead and approved them both anyway.
- 23:13Speaker 2: It's funny though, because it's not being introduced as like
- 23:16Speaker 2: an emergency use authorization, knowing that it's being rushed. You'd
- 23:20Speaker 2: think that they would try to work around that to
- 23:23Speaker 2: cover themselves, knowing that it hasn't been studied, but they're not.
- 23:28Speaker 2: So they're pushing it out. And, you know, just to
- 23:31Speaker 2: kind of back up just a smidge, there are, as
- 23:36Speaker 2: Janet said, four main types of flu viruses in But
- 23:41Speaker 2: under those viruses, there are sometimes subtypes that have like,
- 23:47Speaker 2: and for instance, I'm reading here, 130 for influenza A
- 23:53Speaker 2: subtype alone. So when we say that they don't really
- 23:56Speaker 2: know what they're pinpointing, that's what we're talking about. Like
- 24:00Speaker 2: you can see that there's four groups, four main groups,
- 24:03Speaker 2: but because there's so many subtypes potentially below each main one,
- 24:09Speaker 2: how can they predict? accurately and they can't. And because
- 24:14Speaker 2: the flu vaccine is typically a live attenuated virus, this
- 24:19Speaker 2: is a concern. They say it's weakened. They say it's deadened,
- 24:22Speaker 2: but you.
- 24:22Speaker 1: Know, you can't, you can't possibly get the flu after
- 24:26Speaker 1: getting a vaccine, which is so crazy.
- 24:31Speaker 2: Right. And it's, and that's why every time you see
- 24:33Speaker 2: these mass vaccination campaigns and, you know, the push for flu, well,
- 24:38Speaker 2: you know, cause we're talking about flu and then you
- 24:41Speaker 2: see the cases, the amount of patients that are still
- 24:44Speaker 2: getting sick. And then what does it look like with
- 24:46Speaker 2: their vaccination status? But then they'll come back and they'll say, well,
- 24:49Speaker 2: we didn't say that it was going to completely negate
- 24:53Speaker 2: you from having the flu. We're saying it's going to
- 24:56Speaker 2: keep you out of the hospital and from dying. And
- 24:59Speaker 2: so in the meantime, you have all these people that
- 25:01Speaker 2: are taking these products being told that they're going to
- 25:05Speaker 2: be protected and And then they still end up sick
- 25:08Speaker 2: and or having other health issues.
- 25:11Speaker 1: Or in the hospital.
- 25:13Speaker 2: Or in the hospital, which again, you know, just because
- 25:16Speaker 2: you may not have the flu doesn't mean that you
- 25:17Speaker 2: couldn't have pneumonia or other things because your immune system
- 25:20Speaker 2: gets weakened by these vaccines. And it can cause your
- 25:24Speaker 2: system to go into this inflammatory state and, you know,
- 25:27Speaker 2: et cetera. And because you may have other comorbidities, you
- 25:32Speaker 2: are more high risk of So as soon as you
- 25:34Speaker 2: start injecting yourself, depending on the strain that's chosen that year, and,
- 25:40Speaker 2: you know, you start to really find out very quickly,
- 25:42Speaker 2: what is the efficacy? And some of these studies will
- 25:44Speaker 2: tell you 80 to 90%, but that's just impossible because
- 25:48Speaker 2: you see the amount of people.
- 25:49Speaker 1: It's called lying with statistics. Right.
- 25:53Speaker 2: It's what we call in the nurse's report, magic math.
- 25:55Speaker 2: They do these half-assed studies. Just like you said, they
- 25:59Speaker 2: work around the system. They're told don't change things in
- 26:01Speaker 2: the middle of their study. They do it anyways. They
- 26:04Speaker 2: start cutting out the subjects, right? Okay, well, this person,
- 26:08Speaker 2: we're going to pull them out. We're going to do this.
- 26:10Speaker 2: It's bias.
- 26:12Speaker 1: Which also invalidates the study.
- 26:14Speaker 2: Right. And so people get these studies that are poorly done,
- 26:18Speaker 2: backed by big pharma, who go around the system. And
- 26:22Speaker 2: then they use that as to say, well, this is
- 26:24Speaker 2: the meat and potatoes. It worked. This is the efficacy
- 26:28Speaker 2: that we have. Well, yeah, when you start weeding out
- 26:31Speaker 2: all the trial participants that don't fit your criteria, no shit, right?
- 26:38Speaker 2: Your percentages are going to go up. So I just
- 26:40Speaker 2: find it very interesting. And again, just to point out
- 26:44Speaker 2: that there's so many different subtypes that this is why
- 26:47Speaker 2: the flu vaccine typically has some of the lowest participation
- 26:51Speaker 2: and why it gets forced, especially on healthcare workers. Oh, 100%.
- 26:56Speaker 2: I understand. for that reason. So, yeah.
- 26:59Speaker 1: And you know, I'm glad you brought that up because
- 27:02Speaker 1: during COVID, how many times did they change? And this
- 27:06Speaker 1: same with the flu, they've done this as well, but
- 27:09Speaker 1: how many times did they change? And it was like, Oh,
- 27:12Speaker 1: it's a hundred percent effective. It's 99% effective. Oh, we
- 27:16Speaker 1: found that it's 60% effective. Oh wait, it's 40%. Uh, yeah,
- 27:20Speaker 1: it's about 16% effective. Um, And that has held true
- 27:30Speaker 1: for as long as I have been in healthcare, where
- 27:34Speaker 1: the flu vaccine itself has such low efficacy. And I
- 27:40Speaker 1: think they're going to have a very low turnout to
- 27:44Speaker 1: get this, hopefully, after the COVID debacle and all of
- 27:51Speaker 1: the things that they tried to cover up or bury
- 27:54Speaker 1: or whatever, and like all the lies that they told.
- 27:57Speaker 1: And then here's another vaccine that's exactly 100% just like it.
- 28:05Speaker 1: And it mutates rapidly just like COVID does. And, you know,
- 28:14Speaker 1: how many people do you think are going to be
- 28:17Speaker 1: lining up to try this experimental gene therapy again? knowing
- 28:25Speaker 1: what we know now and what has come out about
- 28:30Speaker 1: the Pfizer stuff?
- 28:32Speaker 2: I mean, I hope the number would be low. I
- 28:34Speaker 2: hope that all the talking and, you know, the continuation
- 28:37Speaker 2: of the conversation of the dangers of mRNA technology, what
- 28:42Speaker 2: we've seen, what people have come forward to tell their
- 28:45Speaker 2: story and how it's impacted them adversely and some who
- 28:48Speaker 2: are no longer with us. I mean, that's really where
- 28:51Speaker 2: this boils down to. mRNA technology has proven significant harm
- 28:56Speaker 2: in death. And people can argue that and say that
- 28:59Speaker 2: there's no causation to that. Well, you can tell that
- 29:01Speaker 2: to the families who have spoken in place of their
- 29:05Speaker 2: loved one who took it because they thought it was
- 29:07Speaker 2: the right thing to do. And so with the flu vaccine,
- 29:10Speaker 2: knowing that it's an endemic, it's going to happen every year.
- 29:15Speaker 2: This is something that is not going to go away.
- 29:17Speaker 2: And it's most likely because we're mass vaccinating and mutating
- 29:21Speaker 2: it further along. You know, it's to show the efficacy
- 29:26Speaker 2: is really the most important. What is your risk versus benefit?
- 29:29Speaker 2: Why would you get a flu vaccine if the efficacy
- 29:33Speaker 2: or how well it works is very low? And one
- 29:35Speaker 2: of the things from the actual CDC website for adults
- 29:39Speaker 2: shows that. that it has a 22 to 34% reduction
- 29:44Speaker 2: in medical visits and 30% reduction in hospitalizations, which if
- 29:50Speaker 2: I'm a percentage person, I mean, is that a good,
- 29:53Speaker 2: is that a good number?
- 29:54Speaker 1: I mean, I would say that- Compared to what percentage
- 29:59Speaker 1: of the population is what I would like to know.
- 30:01Speaker 2: Correct. And what exactly other things potentially could be going on.
- 30:06Speaker 2: And for children, it says that the effectiveness is often higher,
- 30:09Speaker 2: which I beg to differ, and says that they have
- 30:12Speaker 2: a 38% to 41% reduction of medical visits and or
- 30:17Speaker 2: 41% of hospital admissions, which again, we see oftentimes children
- 30:25Speaker 2: do not necessarily respond as maybe somebody who's older when
- 30:30Speaker 2: it comes to the flu, meaning they're not usually as
- 30:32Speaker 2: sick with or without a vaccine typically. And it just
- 30:37Speaker 2: reinforces that this is designed to specifically lower the risk
- 30:43Speaker 2: of severe complications specific to ICU admissions and death. That's
- 30:48Speaker 2: what they're saying that the flu vaccine rollout is really
- 30:52Speaker 2: targeted for. to decrease your risk of severe complications, ICU
- 30:58Speaker 2: admissions and death. So, okay. You know, so maybe as
- 31:02Speaker 2: we go along, we might hit some, hit some numbers
- 31:04Speaker 2: there to see if that is in fact true or not.
- 31:08Speaker 2: When you have this potential technology that is known to
- 31:11Speaker 2: put people in the hospital with severe problems and death.
- 31:16Speaker 1: Right. A hundred percent. So here's the study that got
- 31:20Speaker 1: it approved. Now, how many millions of people are in
- 31:25Speaker 1: the United States alone? There's a lot, right?
- 31:28Speaker 2: 339 million, I believe.
- 31:30Speaker 1: Okay. So their study population was 40,000 people. To me,
- 31:37Speaker 1: that's a pretty freaking small section of the population to
- 31:42Speaker 1: be looking at. And I would want to know, these
- 31:45Speaker 1: are adults that are 50 plus years old that were
- 31:48Speaker 1: in this study. supposedly randomized, supposedly double-blinded study, active control group, blah, blah, blah, blah,
- 31:58Speaker 1: but that's BS. When you read the actual study, the
- 32:03Speaker 1: study parameters were not followed by any shape of the imagination.
- 32:09Speaker 1: So the FDA reported a relative vaccine efficacy rate of 26.6%.
- 32:21Speaker 1: the 95% confidence rate, which that, like I said, very
- 32:31Speaker 1: small trial. It depends on what kind of participants you
- 32:37Speaker 1: put in that trial. Did they have comorbidities? Were they
- 32:41Speaker 1: healthy individuals? Were there different races that were in this study?
- 32:47Speaker 1: Because that hinges a lot on healthcare itself because different
- 32:53Speaker 1: races have more genetic predisposition to certain things. And so
- 33:02Speaker 1: during this study, like I said, lying with statistics was
- 33:06Speaker 1: the big thing. So relative efficacy and absolute risk are
- 33:11Speaker 1: not the same thing. So if you read down this thing,
- 33:16Speaker 1: the control group controversy in here. This is one of
- 33:20Speaker 1: the most important key pieces of this study. The FDA refused,
- 33:27Speaker 1: like I said, Moderna's initial application for this because one
- 33:32Speaker 1: concern was the vaccine that was used, like I said before,
- 33:37Speaker 1: and the older population was And so for the 65 plus,
- 33:42Speaker 1: the CDC has a preferential recommendation, aka the stronger vaccination
- 33:48Speaker 1: for 65 and older, which was not used. So the
- 33:53Speaker 1: control group in this was screwed up from the get-go.
- 33:58Speaker 1: And so the FDA and their refusal for approval said,
- 34:05Speaker 1: explicitly noted that clinical trials in this particular population should
- 34:12Speaker 1: use the actual comparator vaccine or the preferred vaccine relevant
- 34:19Speaker 1: to the standard of care. So they did not even
- 34:21Speaker 1: follow the standard of care recommendation in the study whatsoever.
- 34:27Speaker 1: So that invalidates the study, the trial altogether because the
- 34:32Speaker 1: guidelines weren't followed. And so the the new mRNA vaccine
- 34:41Speaker 1: versus the ordinary standard flu shot, or should this be
- 34:46Speaker 1: the new vaccine versus the best currently recommended vaccine for
- 34:51Speaker 1: that age group? Those were questions that the FDA raised
- 34:54Speaker 1: themselves because it wasn't done properly. And so the 65
- 34:59Speaker 1: and over approval was also like an important part of this.
- 35:05Speaker 1: It's under accelerated approval for them, like I said, because
- 35:12Speaker 1: evidence supporting the 65 plus age indication was based on
- 35:18Speaker 1: comparative immunogenicity rather than the same kind of demonstrated clinical
- 35:27Speaker 1: benefit used for the younger group. So this has not
- 35:31Speaker 1: been studied in anybody that wasn't and over in this trial.
- 35:39Speaker 1: And so that's a problem. But like I said, they
- 35:42Speaker 1: have until 2030 to do their post-marketing study and whatever,
- 35:48Speaker 1: even though the FDA approved this without the final report
- 35:53Speaker 1: even being done. It's not due until May 31st of
- 35:56Speaker 1: 2030 for post-clinical studies. Yeah, that's for an invalid trial.
- 36:04Speaker 2: Well, and, you know, when people start asking us to
- 36:07Speaker 2: cite sources and where do you get your information and
- 36:10Speaker 2: all this other stuff? And, you know, we play devil's
- 36:12Speaker 2: advocate and we discuss these types of trials and show
- 36:16Speaker 2: them this this evidence as I use, you know, air quotes.
- 36:20Speaker 2: You automatically would have just disqualified this out the gate
- 36:24Speaker 2: because they didn't follow evidence. the safety guidelines and the
- 36:28Speaker 2: actual criteria that they're supposed to do when they're rolling
- 36:31Speaker 2: out a product, they completely went ahead and made up
- 36:34Speaker 2: their own rules. And so that should automatically tell you
- 36:37Speaker 2: that this is an invalid trial and that, you know,
- 36:39Speaker 2: you can't really take this study seriously. So for the listeners,
- 36:43Speaker 2: you know, if this is something that you start to
- 36:45Speaker 2: refer to, you know, really look deep into like who's
- 36:47Speaker 2: actually supporting this, meaning who's funding it, usually it's big pharma.
- 36:51Speaker 2: What does the trial size look like? How many people
- 36:54Speaker 2: did they get rid of? Did they change things in
- 36:56Speaker 2: the middle of the trial? As Janet said, you're not
- 36:57Speaker 2: supposed to do. They did it anyways. And then, you know,
- 37:01Speaker 2: other things that they're doing to manipulate the data to
- 37:03Speaker 2: get the results that they just said. would be appropriate
- 37:07Speaker 2: for this particular age group, but then have the protections
- 37:11Speaker 2: in place to say, well, we still get another four
- 37:15Speaker 2: and a half years to try and see if this
- 37:19Speaker 2: is in fact going to meet in other areas. We're
- 37:22Speaker 2: going to continue this trial, if you will, while we're
- 37:25Speaker 2: pumping this into people and telling you it's safe and
- 37:31Speaker 2: effective for When we have no proof that, I mean,
- 37:34Speaker 2: like how long was it actually done? How long, what
- 37:37Speaker 2: was the length?
- 37:38Speaker 1: That is a good question because that is not in
- 37:41Speaker 1: there to bulge to the public information. But here's another
- 37:47Speaker 1: little caveat to their study. Nobody who is an organ
- 37:55Speaker 1: transplant recipient was in this study. or during the COVID
- 38:02Speaker 1: thing when they're like, Oh, if you're, if you've had
- 38:05Speaker 1: a transplant, you're completely fine to get this. It's safe
- 38:08Speaker 1: and effective. I had a friend who had had a
- 38:12Speaker 1: liver transplant and, and I was like, I would not
- 38:16Speaker 1: absolutely would not because I guarantee you that that study
- 38:22Speaker 1: group was not in this study. And I guarantee you
- 38:27Speaker 1: that even if there was one, that's too small of
- 38:32Speaker 1: a group to prove safety and efficacy. Nursing mothers, you know,
- 38:39Speaker 1: immunocompromised people, like all of the groups that should be included,
- 38:45Speaker 1: were they in this study? Nope.
- 38:49Speaker 2: Yeah. And of course, during the pandemic, I was a
- 38:52Speaker 2: heart transplant nurse. So that really hits hard because those
- 38:55Speaker 2: patients were so sick and usually were very, you know,
- 38:59Speaker 2: in medicine, we're told certain very vulnerable populations would not
- 39:03Speaker 2: meet criteria depending on their level of illness or sickness. Right.
- 39:07Speaker 2: And so to know that we push that on them
- 39:11Speaker 2: and I saw what it did to them, harm and death,
- 39:14Speaker 2: you know, it's just like you said, it's it's on
- 39:17Speaker 2: a whole nother level of ethics and morals and moral
- 39:21Speaker 2: injury that you just can't fathom unless you actually watched
- 39:25Speaker 2: it yourself unfold. And so to know that they're going
- 39:28Speaker 2: to do this again or try it again. because unfortunately
- 39:31Speaker 2: for those that may not know transplant recipients transplant, you know,
- 39:36Speaker 2: if you're on the waiting list or you're considered, you know,
- 39:39Speaker 2: a donor, they're going to make you get the vaccines.
- 39:42Speaker 2: They're going to push it. And that's what happened during
- 39:45Speaker 2: the pandemic and why we saw so much harm. to
- 39:48Speaker 2: these vulnerable populations. So it's really concerning to know that
- 39:51Speaker 2: these people were not included. They have no idea what
- 39:54Speaker 2: this would do to them, but they're going to be
- 39:57Speaker 2: one of the first groups that they're going to force
- 39:59Speaker 2: to get it in order for them to continue with
- 40:02Speaker 2: their treatment as a donor or transplant, excuse me.
- 40:05Speaker 1: And it makes no sense to me why they haven't
- 40:09Speaker 1: changed that standard of care, if you will, where it's
- 40:14Speaker 1: mandated to give this investigational vaccine type to transplant patients
- 40:25Speaker 1: when those patients are already having to deal with a
- 40:29Speaker 1: possible rejection of the organ that they're receiving and all
- 40:34Speaker 1: of the things that you have to watch them so closely.
- 40:37Speaker 1: And it makes no sense why they have not already
- 40:41Speaker 1: been like, you know what, here's all the Pfizer vaccines.
- 40:45Speaker 1: studies and data that's coming out and all the information,
- 40:50Speaker 1: we need to not make these people get that because
- 40:53Speaker 1: they're already at very high risk for all kinds of
- 41:00Speaker 1: things when they're getting a transplant anyway.
- 41:03Speaker 2: So when I pushed back during the pandemic and I
- 41:07Speaker 2: was coming to the surgeons and I was asking questions
- 41:11Speaker 2: and You know, the patients had questions. They were concerned
- 41:14Speaker 2: that they didn't want to get the vaccine. There was
- 41:16Speaker 2: a lot of unknowns. You know, the surgeons were very
- 41:19Speaker 2: much regimental in how they explained it, that they are
- 41:24Speaker 2: on anti-rejection meds. Their immune system is already being put
- 41:28Speaker 2: in an immunocompromised state always. They're always going to be
- 41:32Speaker 2: considered high risk. And so they would say, you know,
- 41:35Speaker 2: I'm not going to put an organ in someone who
- 41:39Speaker 2: doesn't have these vaccines to prevent them against these preventable diseases.
- 41:44Speaker 2: And I'm not gonna have, you know, this immunocompromised by
- 41:47Speaker 2: the anti-rejection meds and other things that they're given, be
- 41:53Speaker 2: so low in their immunity that they're more susceptible to
- 41:55Speaker 2: get hepatitis, they're more susceptible to get flu, COVID. The
- 41:59Speaker 2: thing is, though, is that when you're injecting this stuff
- 42:02Speaker 2: into them, you're not just injecting, you know, what you're
- 42:05Speaker 2: trying to avoid, again, air quotes, you're giving them adjuvants,
- 42:08Speaker 2: you're giving them aluminum, You're giving them aborted fetal cells.
- 42:12Speaker 2: There's all this crap in it. And you're usually giving multiple.
- 42:16Speaker 2: And you continue to give it to them. As a
- 42:19Speaker 2: matter of fact, the COVID-19 patients that have the most
- 42:23Speaker 2: injections are the transplant patients that I see come through
- 42:26Speaker 2: our program. So like you said, it's really unfortunate because
- 42:29Speaker 2: they're already so immunocompromised. But from the surgeon's standpoint, they're
- 42:32Speaker 2: constantly going to be vulnerable and they don't want to
- 42:35Speaker 2: treat patients who are more susceptible to have these diseases,
- 42:39Speaker 2: but here's my thing. And again, not to say that
- 42:42Speaker 2: anybody wants hepatitis or, you know, the flu or, you know, tuberculosis.
- 42:47Speaker 2: I'm not, I'm not saying that, but are these things
- 42:50Speaker 2: not treatable? Right.
- 42:52Speaker 1: And that's, and that's my whole thing with why would
- 42:56Speaker 1: you want to get a COVID vaccine or flu vaccine anyway,
- 43:01Speaker 1: because the symptoms are so mildly, compared to what you
- 43:08Speaker 1: get status post-vaccination unless you are a vulnerable population patient.
- 43:17Speaker 1: But here's the thing, and I have this question. So
- 43:20Speaker 1: with the transplant patients and with vaccines like the COVID vaccine,
- 43:25Speaker 1: which this is probably going to be the same with
- 43:28Speaker 1: the flu, it settles, the spikes settle, especially in beta cells.
- 43:35Speaker 1: You have beta cells in your heart, in your liver,
- 43:38Speaker 1: in your brain, and all of your major organs. And
- 43:43Speaker 1: what is normally on the list for a transplant patient?
- 43:48Speaker 1: A major organ. So you're giving something that's going to settle,
- 43:53Speaker 1: spike proteins in the organ that they're just getting. Why?
- 43:59Speaker 1: You're wasting an organ.
- 44:02Speaker 2: Well, and one of the things that I think we're
- 44:05Speaker 2: just seeing the tip of the iceberg on and the
- 44:07Speaker 2: spin that you're going to see it pushed in the
- 44:12Speaker 2: media and from these three letter agencies is that, you know,
- 44:17Speaker 2: the need for organs has increased. Right. Absolutely.
- 44:20Speaker 1: Absolutely.
- 44:21Speaker 2: Because of the pandemic. And the first thing that they're
- 44:25Speaker 2: saying is, oh, it's because of COVID. It's because these
- 44:27Speaker 2: people had horrendous COVID. And where I'm not discrediting that,
- 44:30Speaker 2: where I'm not saying that there aren't cases of moderate
- 44:33Speaker 2: to severe COVID viral cases. illnesses that have affected people poorly.
- 44:38Speaker 2: And again, it's because they didn't receive the right treatment.
- 44:41Speaker 2: It's because they were turned away. It's because they weren't
- 44:44Speaker 2: treated accordingly. So let's not get it twisted. It wasn't
- 44:47Speaker 2: because of the virus. It was because of lack of
- 44:49Speaker 2: being medically, you know, accepted and cared for and received
- 44:53Speaker 2: delayed treatment. However, we'll play the game and say, okay,
- 44:56Speaker 2: the diseases, the virus, excuse me, but really the amount
- 45:00Speaker 2: of people that received the vaccine, uh, they're, health issues
- 45:06Speaker 2: have exponentially, you know, exploded. And, and then if you
- 45:10Speaker 2: add onto that, that they also had moderate to severe
- 45:13Speaker 2: COVID with receiving multiple vaccines, they are a ticking time bomb.
- 45:18Speaker 2: And so this, again, with the mRNA technology being added
- 45:21Speaker 2: to other vaccines, and if you get multiple vaccines with
- 45:25Speaker 2: this in it, you are going to be in a
- 45:27Speaker 2: constant state of producing spike for the, for, for majority,
- 45:30Speaker 2: I'm sure that, And it's going to continue to cause
- 45:33Speaker 2: significant health issues. And we see it every day. I mean,
- 45:36Speaker 2: we have numbers off the charts. Look at, I literally
- 45:38Speaker 2: just went to a conference, a cardiology conference and the
- 45:41Speaker 2: slides that we were shown in the conference from multiple
- 45:45Speaker 2: well-known cardiac doctors. Okay. So they're, they're dealing with these
- 45:50Speaker 2: patients from all over the United States. It shows a
- 45:53Speaker 2: major spike in 2021 in all of their slides of
- 45:59Speaker 2: mortality in Right. And people are like, well, that's weird.
- 46:02Speaker 2: What happened in 2021? I don't know. So again, you know,
- 46:07Speaker 2: and then it's kind of trending down a little bit.
- 46:09Speaker 2: But again, these patients have higher, they're always sick, you know,
- 46:15Speaker 2: and so it may not kill you right away, but
- 46:18Speaker 2: it's slowly dragging your health down and over time causing
- 46:22Speaker 2: significant health issues. And that I believe is truly from
- 46:26Speaker 2: the mRNA technology. Right.
- 46:28Speaker 1: And for people who don't understand, like when we're talking
- 46:32Speaker 1: about how your immune system basically becomes like hyperactive, right?
- 46:41Speaker 1: And so I like to call it kicking up dust.
- 46:44Speaker 1: If you can imagine like a giant pile of sawdust
- 46:48Speaker 1: on the floor, which is your body and all of
- 46:52Speaker 1: the toxins, pathogens, whatever you want to call it. And
- 46:57Speaker 1: we step in it. stomp in it, right? So we
- 47:00Speaker 1: get the vaccine and that kicks up literally all of
- 47:05Speaker 1: that cell dust, all of those pathogens, toxins, whatever. And
- 47:10Speaker 1: they're running rampant in your system because your immune system
- 47:13Speaker 1: is shot, which is even in their own documents that
- 47:19Speaker 1: they were trying to hide for 75 years from the
- 47:22Speaker 1: COVID stuff, where it reduces your body's Immunity, getting vaccinated
- 47:32Speaker 1: and especially multiple doses reduces your immunity in your body.
- 47:39Speaker 1: So you're more susceptible to all of the kicked up dirt.
- 47:45Speaker 1: You know what I'm saying? And so are they going
- 47:47Speaker 1: to make this the same way since it's a flu vaccine?
- 47:50Speaker 1: It's going to be a seasonal yearly thing when this
- 47:54Speaker 1: gets the final go ahead and put it out there.
- 47:58Speaker 1: everybody's going to get this every single year. Elderly patients,
- 48:02Speaker 1: the hospital's going to force it. Doctors, officers are going
- 48:05Speaker 1: to force it because they get paid. The more people
- 48:09Speaker 1: they vaccinate, the more money that they make. So here's
- 48:13Speaker 1: some interesting numbers from their study. And this should give
- 48:18Speaker 1: you pause. If it doesn't, you're not listening properly. So
- 48:23Speaker 1: these are reactions, local reactions that people are having from
- 48:27Speaker 1: this study that got approved. So with the mRNA flu vaccine, 67.5%
- 48:35Speaker 1: of the participants got reactions compared to 32% that were
- 48:44Speaker 1: using the old time flu vaccine. That's a hell of
- 48:48Speaker 1: a jump. Okay. Okay. And then systemic reactions, which means body-wide,
- 48:53Speaker 1: 58% with the mRNA technology and 32% with the regular.
- 49:01Speaker 1: Those numbers should give you pause because in every category
- 49:07Speaker 1: almost in this study, the mRNA was so much higher
- 49:14Speaker 1: than what the regular vaccine was. Now, the regular vaccine
- 49:17Speaker 1: is not very effective at anything. Um, but a lot
- 49:21Speaker 1: of people were just getting like flu symptoms or, you know, whatever.
- 49:26Speaker 1: This study is frightening when you actually read everything that
- 49:30Speaker 1: is included in here for serious life-threatening adverse events. 2.2%
- 49:41Speaker 1: versus the 1.9% for the regular. That doesn't sound like much,
- 49:47Speaker 1: but this person was also not during their 42-day study parameter.
- 49:56Speaker 1: This person had a serious reaction outside of 42 days.
- 50:01Speaker 1: So they're like, well, maybe we shouldn't include this. I
- 50:06Speaker 1: don't know. So 42 days is how long you're watching somebody.
- 50:11Speaker 2: Yeah, it's it's quite it's quite criminal. I mean, and
- 50:15Speaker 2: a lot of people will probably think that, you know,
- 50:18Speaker 2: what's the big deal or, you know, it's it's obviously
- 50:21Speaker 2: a good amount of time. Right. Because you have most studies.
- 50:27Speaker 2: are less than that.
- 50:28Speaker 1: Right.
- 50:29Speaker 2: So, you know, they may argue that, but here's the thing.
- 50:31Speaker 2: Like when you have a flu season, typically we are
- 50:36Speaker 2: alerted to that between October and maybe March. And, you know,
- 50:41Speaker 2: you start rolling out the vaccines, you start making, you know, initiatives,
- 50:46Speaker 2: putting them in place goals. If I, if I say,
- 50:48Speaker 2: you know, you know, we're trying to get, you know,
- 50:50Speaker 2: units and, you know, whole entire hospitals vaccinated. We're trying
- 50:54Speaker 2: to make sure that every time you go to CVS
- 50:56Speaker 2: or Walgreens or the grocery store, you're being prompted to
- 50:59Speaker 2: get $ 10, $ 20 to go get your flu vaccine. You know,
- 51:03Speaker 2: they're doing all these things to like force and push and,
- 51:06Speaker 2: you know, do all, you know, get people to get it. And.
- 51:10Speaker 2: For the most part, they say that if you have
- 51:12Speaker 2: a true reaction to the vaccines, it would happen within
- 51:15Speaker 2: a 24-hour period. But again, we're not talking about a
- 51:20Speaker 2: typical vaccine. We're talking about mRNA technology that is designed
- 51:24Speaker 2: to rapidly produce vaccines. rapidly push you, you know, with
- 51:28Speaker 2: the particular virus that it's targeting. And you have to
- 51:32Speaker 2: look at what that looks like for people who have
- 51:35Speaker 2: multiple comorbidities, who may be more sensitive to this stuff. So,
- 51:39Speaker 2: you know, I just think that that timeframe, you And again,
- 51:46Speaker 2: they're getting away with this because they're saying, well, we're
- 51:49Speaker 2: going to continue to monitor it and we have until
- 51:51Speaker 2: 2030 to do it. But again, anyone that gets it,
- 51:55Speaker 2: if you're listening, you are going to be the subject.
- 51:58Speaker 2: That is what it's going to be because this is
- 52:00Speaker 2: how they monitor it. You know, depending on where you
- 52:02Speaker 2: get it, they're going to document that they gave it
- 52:04Speaker 2: to you. They're going to document that they gave you
- 52:06Speaker 2: a vaccine insert to give you the informed consent, which
- 52:09Speaker 2: we know is a lie. And then they're going to
- 52:11Speaker 2: tell you if there's any issues, go ahead and take
- 52:13Speaker 2: Tylenol or, you know, severe issues. They may, may ask
- 52:17Speaker 2: you to report it to VAERS, which most don't even
- 52:19Speaker 2: know what that is. And then they're going to continue to,
- 52:22Speaker 2: to push it. And a lot of people will be
- 52:24Speaker 2: gaslit and told that it's has nothing to do with
- 52:27Speaker 2: the vaccine.
- 52:28Speaker 1: I would just say that.
- 52:29Speaker 2: Yep.
- 52:30Speaker 1: Well, I'm glad you said that because in the study,
- 52:34Speaker 1: there were 0.3% deaths in both groups. However, the FDA
- 52:40Speaker 1: upon their review assessed that none were actually vaccine related.
- 52:47Speaker 1: They couldn't link them to the vaccine.
- 52:49Speaker 2: They don't ever link them.
- 52:51Speaker 1: So seriously. Yeah. Um, so they knew in the study, uh,
- 52:59Speaker 1: myocarditis and pericarditis again, just like the COVID stuff. Um,
- 53:05Speaker 1: so there were 10, uh, in the mRNA, there were
- 53:10Speaker 1: seven in the other. FDA again was like, well, you know,
- 53:14Speaker 1: we're going to go ahead and know we're going to
- 53:18Speaker 1: look the other way because, oh, there was no signal.
- 53:21Speaker 1: There was no indication that the vaccine actually could have
- 53:25Speaker 1: caused this. Wasn't that a thing during COVID? Yes, it was.
- 53:33Speaker 1: I was on, I was watching the FDA meeting before
- 53:38Speaker 1: they did their actual emergency use authorization where they brought
- 53:44Speaker 1: up these things from studies and then they're telling people, oh, no,
- 53:48Speaker 1: it's nothing. And then after all these people start getting
- 53:52Speaker 1: pericarditis and myocarditis, they're like, oh, shoot. Well, that might
- 53:59Speaker 1: have been in our study data. Same thing here.
- 54:03Speaker 2: I'm just genuinely curious. If you sign yourself up for
- 54:07Speaker 2: a study, if you sign a family member up or
- 54:10Speaker 2: you are the family member or the spouse and something
- 54:13Speaker 2: significantly happens to them where we're talking, they die and
- 54:18Speaker 2: you are told that this couldn't have been the only
- 54:23Speaker 2: new thing that you were trying in a trial. I
- 54:25Speaker 2: would love to have somebody on the show that maybe
- 54:29Speaker 2: has experienced that in the past because I cannot fathom that.
- 54:32Speaker 2: being okay with that or, or assuming that other people
- 54:37Speaker 2: haven't had this happen in the past and would be
- 54:39Speaker 2: willing to talk about it. It's almost like there's a
- 54:41Speaker 2: gag order or something on that. I don't know. Maybe,
- 54:43Speaker 2: maybe this is part of how they run the trial.
- 54:45Speaker 1: I'm sure.
- 54:46Speaker 2: But it's like so interesting to me that everyone's like, oh, okay.
- 54:48Speaker 2: So you say it's not. All right. So it can't
- 54:50Speaker 2: be the only, the only thing that's different is the
- 54:53Speaker 2: vaccine that you injected into my spouse and they're now gone,
- 54:57Speaker 2: but you know, it can't be that. So I just
- 54:58Speaker 2: keep having that.
- 55:00Speaker 1: That's literally in every category on here where it was
- 55:04Speaker 1: reviewed because there was one case of the Jillian Barr syndrome.
- 55:09Speaker 1: And the 42 days is the predefined 42-day risk window.
- 55:19Speaker 1: So if you're going to have something that has to
- 55:20Speaker 1: happen in 42 days or it's not considered... whatever. So
- 55:25Speaker 1: the FDA looked at this also and they were like,
- 55:28Speaker 1: Oh no, couldn't possibly be because it's past the 42
- 55:33Speaker 1: day risk window.
- 55:35Speaker 2: Where do they get the 42 days from? So magically
- 55:39Speaker 2: on the 40th day, there's no issues. Right.
- 55:41Speaker 1: A hundred percent. That's their arbitrary number. Kind of like, uh,
- 55:46Speaker 1: NASA and space and all this stuff that they make up. Um,
- 55:50Speaker 1: math doesn't make sense. So, um, With 40,000 people in
- 55:57Speaker 1: this study, and again, you said 369 million people?
- 56:03Speaker 2: 339 million people.
- 56:04Speaker 1: In the United States, that's a very small clinical number
- 56:10Speaker 1: to assess safety. And then anything outside of this 42-day
- 56:18Speaker 1: risk window is going to be considered... nolan void in
- 56:23Speaker 1: this study that's gonna their post-marketing study that's not due
- 56:27Speaker 1: until 2030 they can watch them sure but it's gonna
- 56:34Speaker 1: be like all these other ones where they're like oh
- 56:37Speaker 1: couldn't possibly be related to that no no no no
- 56:40Speaker 1: can't be i.
- 56:42Speaker 2: Have so much to say about that but i'm just.
- 56:44Speaker 1: Gonna So, this is the same thing as the COVID
- 56:48Speaker 1: one because, again, in this, they're going, oh, well, it
- 56:52Speaker 1: stays at the injection site. It can't go anywhere else.
- 56:55Speaker 1: It doesn't cross the blood-brain barrier. It doesn't do this.
- 56:59Speaker 1: It doesn't do that. Yes, it does. It causes spikes 100%.
- 57:05Speaker 1: It's the exact same technology that they used for COVID,
- 57:09Speaker 1: just different ingredients. This one's focused on the flu, which
- 57:15Speaker 1: And old textbooks of flu and COVID are the exact
- 57:17Speaker 1: same thing. Just saying. So, you know, so the lipid
- 57:24Speaker 1: nanoparticle questions, like what happens? There were some legitimate questions
- 57:31Speaker 1: that arise from that. I have questions on that because
- 57:36Speaker 1: how's your biodistribution? Where all does that go in your body?
- 57:40Speaker 1: What happens to that in your body? Um, what does
- 57:44Speaker 1: it do for inflammatory signaling in your body? Yeah, we
- 57:48Speaker 1: already know what it did with the COVID one, right? Um,
- 57:53Speaker 1: innate immune of that activation. It can actually irritate your
- 57:57Speaker 1: immune system and have it go berserk. Like, like I said,
- 58:01Speaker 1: kicking up, it's all dust. Um, how about repeated exposure?
- 58:06Speaker 1: What does that do with these lipid nanoparticles? Do they
- 58:10Speaker 1: build up? Do they cause, um, peripheral artery disease do
- 58:15Speaker 1: they cause uh you know what am i trying to
- 58:19Speaker 1: say uh yeah like the plaque buildup.
- 58:23Speaker 2: Oh you're talking about like carotid stenosis or just you
- 58:27Speaker 2: know the yeah.
- 58:29Speaker 1: Um arteriosclerosis whatever could it cause that we don't know
- 58:33Speaker 1: because it's never been studied um tissue distribution where what
- 58:37Speaker 1: all tissues are involved in this where does it go
- 58:40Speaker 1: Does it settle in the tissues in what parts of
- 58:43Speaker 1: the body? That's not being studied either. What's the pharmacokinetics
- 58:48Speaker 1: behind it? Is there anything that is toxic or carcinogenic
- 58:56Speaker 1: or anything like that? Because this is new technology. We
- 58:58Speaker 1: don't know. What does it do with your lipid metabolism?
- 59:03Speaker 1: Especially for people who get multiple doses. And if this
- 59:07Speaker 1: lipid technology stays in your body, what is that going
- 59:11Speaker 1: to do? Especially if it's attacking your beta cells, which
- 59:15Speaker 1: your beta cells in your liver are the gatekeepers to
- 59:19Speaker 1: your liver to say yes or no, to bring cholesterol in,
- 59:23Speaker 1: to break it down as needed by your body. So
- 59:27Speaker 1: if those are destroyed, what's that going to do to
- 59:30Speaker 1: the molecules that are floating around you in your bloodstream? No,
- 59:34Speaker 1: don't know. Nobody's studying it. So there's all kinds of
- 59:38Speaker 1: questions from this lipid nanoparticle technology that are not being studied.
- 59:45Speaker 1: And if they are being studied, they're certainly not going
- 59:47Speaker 1: to be published if they're not favorable to pharma. You
- 59:51Speaker 1: know what I mean?
- 59:54Speaker 2: Yeah, it's, it's definitely, um, just some really good information
- 1:00:00Speaker 2: to just continue to highlight how poorly the studies are,
- 1:00:04Speaker 2: how they lack the ethical standards and guidelines and how
- 1:00:09Speaker 2: they're given this pass, if you will, to extend years
- 1:00:14Speaker 2: past a study and that anytime you hear something is
- 1:00:17Speaker 2: being rushed when it comes to a product in general,
- 1:00:23Speaker 2: that usually doesn't have a good connotation to it. And
- 1:00:26Speaker 2: also when we know that we had the COVID-19 mRNA
- 1:00:31Speaker 2: bioweapon rushed, what that looked like and how this unfolded. So,
- 1:00:37Speaker 2: you know, I really hope that people understand that, you know,
- 1:00:41Speaker 2: and they will say that you have to have, you know,
- 1:00:44Speaker 2: the live virus to shed and that these COVID-19 mRNA products, again,
- 1:00:49Speaker 2: I'm referencing that because we do know that is, that
- 1:00:53Speaker 2: it doesn't cause viral shedding, that the mRNA technology does
- 1:00:57Speaker 2: not cause viral shedding is what they'll tell you. However,
- 1:01:01Speaker 2: there have been so many instances and studies that will
- 1:01:05Speaker 2: say that it can't really prove that it doesn't. And
- 1:01:10Speaker 2: that there are instances between an unvaccinated spouse and a
- 1:01:15Speaker 2: vaccinated spouse that there's some things here that cross over.
- 1:01:19Speaker 2: And so- when we start saying, oh, well, it's not
- 1:01:23Speaker 2: going to matter because they're only going to give it
- 1:01:25Speaker 2: to the ages 50 years and older. If they're injecting
- 1:01:28Speaker 2: all these people and then you're around them, we don't
- 1:01:31Speaker 2: have proof. If they're going to start shedding all over
- 1:01:33Speaker 2: you and then you start to have mRNA technology somehow,
- 1:01:37Speaker 2: then that's a concern and that's against my consent. So
- 1:01:40Speaker 2: this is why we are very much on edge about
- 1:01:43Speaker 2: it and don't want this mRNA technology being put into
- 1:01:46Speaker 2: everything because then we start questioning You know, are we
- 1:01:51Speaker 2: protected or is this something that's going against our bodily
- 1:01:54Speaker 2: autonomy without this potentially cause viral shedding and spread to
- 1:01:59Speaker 2: the unvaccinated? Right.
- 1:02:00Speaker 1: A hundred percent. And, you know, that is a very valid,
- 1:02:06Speaker 1: valid point, because, again, if we are a society where
- 1:02:11Speaker 1: we are supposed to be getting informed consent and they're
- 1:02:16Speaker 1: developing a product that they know has viral shedding um
- 1:02:22Speaker 1: and so now they're wanting to do plants and they're
- 1:02:26Speaker 1: wanting to do all of our farm animals for food
- 1:02:30Speaker 1: and and whatever um without our consent because again they
- 1:02:35Speaker 1: don't have to tell you that they're putting it in
- 1:02:37Speaker 1: your plants or vaccinating farm animals or whatever all of
- 1:02:41Speaker 1: this stuff um and so that raises a lot of
- 1:02:45Speaker 1: ethical questions for me and what Is your end goal
- 1:02:52Speaker 1: government entities for doing this? Is it population control? Is
- 1:03:01Speaker 1: it something much more nefarious than that? I don't know.
- 1:03:06Speaker 1: Is it mind control? We don't know because studies have
- 1:03:11Speaker 1: come out about people who got the COVID vaccine jabs
- 1:03:16Speaker 1: and boosters and whatever, and how it has adversely affected
- 1:03:21Speaker 1: their brain and their ability to control anger and emotions
- 1:03:29Speaker 1: and whatever. So is this purposeful?
- 1:03:36Speaker 2: Well, and you know, people may hear what you just
- 1:03:38Speaker 2: said and think that we're absolutely batshit crazy. And people
- 1:03:42Speaker 2: will say, Oh, well these, you know, conspiracy theorists and
- 1:03:44Speaker 2: the tinfoil hat wearers. And, you know, I probably 10
- 1:03:49Speaker 2: years ago would have questioned it as well, because some
- 1:03:51Speaker 2: of the things you hear, you're like, this is, this
- 1:03:53Speaker 2: is insane that they would openly do this and like
- 1:03:57Speaker 2: people wouldn't catch on. But now, you know, again, with
- 1:04:00Speaker 2: the mRNA technology and the only thing I can link
- 1:04:04Speaker 2: it to is the COVID-19 vaccine. You know, when you
- 1:04:06Speaker 2: ask what exactly is the goal, When people start saying depopulation,
- 1:04:11Speaker 2: they get the side eye. But listen, it has caused hundreds... Well,
- 1:04:19Speaker 2: in my opinion, I think it's caused millions of deaths.
- 1:04:22Speaker 2: We also have seen the drop in healthy births. We've
- 1:04:26Speaker 2: seen infertility issues on the rise.
- 1:04:29Speaker 1: I was going to say sterilization.
- 1:04:31Speaker 2: We've seen all of these things that basically... have an
- 1:04:34Speaker 2: end result of a decreased population. And so this is
- 1:04:39Speaker 2: why people are saying that because they are seeing a
- 1:04:42Speaker 2: correlation since 2020, 2021, when the vaccine rolled out and
- 1:04:47Speaker 2: how people have been affected that you can look at
- 1:04:49Speaker 2: the trends, although some of it has been taken down
- 1:04:52Speaker 2: by the three letter agencies because it's not, you know,
- 1:04:55Speaker 2: ready to be shown. But you can talk to anyone
- 1:04:59Speaker 2: and most people will tell you that they've noticed some
- 1:05:02Speaker 2: sort of change related to people being harmed, people dying,
- 1:05:06Speaker 2: the fertility rates going down. Okay. So that's, I just
- 1:05:09Speaker 2: want to like reinforce that because I know when people
- 1:05:11Speaker 2: hear that, they're like, that sounds absolutely crazy. But there's
- 1:05:14Speaker 2: a reason why people are saying it is because they're
- 1:05:17Speaker 2: actually seeing it and it's coming out. I just did
- 1:05:19Speaker 2: an episode where we talked about closing down OB units.
- 1:05:23Speaker 2: My hospital was one of them. Another one in the
- 1:05:26Speaker 2: panhandle of Florida. There's other states that are closing down
- 1:05:29Speaker 2: these units and they're saying, oh, well, you know, budget
- 1:05:31Speaker 2: cuts this and that. But when you do the math,
- 1:05:33Speaker 2: when you actually investigate it, it's because the amount of
- 1:05:37Speaker 2: live births are decreasing. We are not dramatically right. We're
- 1:05:42Speaker 2: not meeting the expectation to continue the population. And they'll say,
- 1:05:46Speaker 2: you know, some groups are maybe having more babies and others,
- 1:05:48Speaker 2: not just crediting that, but as a whole population. We
- 1:05:51Speaker 2: are significantly losing live births. There's 28 percent of, you know,
- 1:05:57Speaker 2: the millennial Gen Z age group, I believe that they
- 1:06:01Speaker 2: said has had aborted babies like that population has been
- 1:06:06Speaker 2: recognized as 28 percent, you know, being purposely aborted. removed
- 1:06:11Speaker 2: um from earth uh but then there's these other products
- 1:06:15Speaker 2: that we've seen that have caused harm and people to
- 1:06:17Speaker 2: have um the inability to have children or they they
- 1:06:20Speaker 2: try to carry and there's a miscarriage or something happens so.
- 1:06:23Speaker 1: Or or the medication that they gave me during my
- 1:06:28Speaker 1: appendectomy that they did not tell me that they were
- 1:06:30Speaker 1: giving which could cause my birth control to not work
- 1:06:34Speaker 1: or could cause sterility not that i want to have
- 1:06:36Speaker 1: any more children i don't but i'm saying There's all
- 1:06:40Speaker 1: these things. And population control is real. Eugenicists believe in it.
- 1:06:48Speaker 1: Bill Gates is a eugenicist. And he has been involved
- 1:06:53Speaker 1: with mRNA technology studies since 2012, ladies and gentlemen. He's
- 1:07:00Speaker 1: also inserted himself wanting to give the mRNA to cattle.
- 1:07:08Speaker 1: And whatever, because he thinks he's the world's leading scientist.
- 1:07:13Speaker 1: He's not a scientist and neither is Bill Nye the
- 1:07:15Speaker 1: science guy, as a matter of fact. But he is
- 1:07:19Speaker 1: a eugenicist and he does believe in population control as
- 1:07:24Speaker 1: well as a lot of other people that do. That's
- 1:07:26Speaker 1: why it is a very valid question to ask.
- 1:07:30Speaker 2: Right. And again, where there's risk, there must be choice.
- 1:07:33Speaker 2: And to know that these things have the potential to
- 1:07:36Speaker 2: cause such harm. and death is why people do not
- 1:07:40Speaker 2: want them mandated, do not want them forced, do not
- 1:07:42Speaker 2: want them to be on the vaccine schedules, do not
- 1:07:45Speaker 2: want to have to get injected to be a productive
- 1:07:47Speaker 2: member of society. People want a choice to be able
- 1:07:50Speaker 2: to use other alternatives to protect themselves. And again, we're
- 1:07:54Speaker 2: not saying that if you have done your due diligence
- 1:07:57Speaker 2: and you have your informed consent and you feel like
- 1:08:00Speaker 2: this is right up your alley, go for it. You
- 1:08:02Speaker 2: have the right to get it. But this is the
- 1:08:05Speaker 2: all these things we're talking about is why a majority
- 1:08:07Speaker 2: of people don't trust science anymore. They don't trust since
- 1:08:10Speaker 2: the pandemic. You know, they've seen what happens with the
- 1:08:13Speaker 2: mRNA technology and to know that they are pushing it
- 1:08:16Speaker 2: on to go into the flu. And like Janet said,
- 1:08:18Speaker 2: they are looking at putting at into the childhood vaccination
- 1:08:22Speaker 2: schedule is absolutely terrifying because there are states that have
- 1:08:27Speaker 2: removed exemptions. They've removed the opportunity to be in society
- 1:08:33Speaker 2: unless you have them. So people are being pigeonholed to
- 1:08:36Speaker 2: make these decisions to get it. And then when it happens,
- 1:08:41Speaker 2: you have no one to sue because of the 1986 Act,
- 1:08:44Speaker 2: the manufacturer liability. And so this is why it's so
- 1:08:47Speaker 2: important people understand that if you decide to move forward
- 1:08:51Speaker 2: with it and something happens, which is evidenced by what
- 1:08:55Speaker 2: mRNA technology has done and what it continues to do,
- 1:08:58Speaker 2: you are left picking up the pieces by yourself. No
- 1:09:02Speaker 2: one is coming to save you. And these people now
- 1:09:04Speaker 2: are living with lifelong health issues until they die. And
- 1:09:09Speaker 2: was it worth it? Is the risk versus benefit? Does
- 1:09:12Speaker 2: it even make sense? It may make sense for an
- 1:09:14Speaker 2: 85 year old with 12 comorbidities. Who's in a nursing
- 1:09:17Speaker 2: home that he gets it. I don't know that. Well,
- 1:09:20Speaker 2: I have a personal opinion about it, but you know,
- 1:09:22Speaker 2: that is different than, you know, a six month old
- 1:09:25Speaker 2: or a 30 year old who otherwise is healthy. So
- 1:09:27Speaker 2: to group everyone in the same, you know, group to
- 1:09:32Speaker 2: do this is where we have concerns. So for again,
- 1:09:35Speaker 2: For them to say, oh, only the age of 50
- 1:09:37Speaker 2: years and older or really targeting the 65-year-old or in group,
- 1:09:41Speaker 2: we all know that that's not going to stand. It's
- 1:09:43Speaker 2: going to change. And then they're going to continue pushing
- 1:09:46Speaker 2: it out on other things. And so this is why
- 1:09:48Speaker 2: it's so important people have these conversations. You have to
- 1:09:51Speaker 2: have the informed consent and to understand that they don't
- 1:09:53Speaker 2: know the data. They don't have enough data. They just
- 1:09:56Speaker 2: told you that in the study that's approved it.
- 1:09:58Speaker 1: Well, you want to hear something? Moderna did another study
- 1:10:03Speaker 1: that's just, 65 years and up. Guess how many people
- 1:10:07Speaker 1: were in that study?
- 1:10:08Speaker 2: Oh, bless. Well, the first one was 40,000. So is
- 1:10:11Speaker 2: it half that? 20,000? 2,991 people. Less than 3,000 people
- 1:10:14Speaker 2: studied in the 65 and older category.
- 1:10:15Speaker 1: A study all by itself. So here's another thing. The
- 1:10:18Speaker 1: mouse study. People have probably seen that floating all over
- 1:10:36Speaker 1: social media. There's, that was definitely done. However, and another,
- 1:10:43Speaker 1: this is another study that did not follow good laboratory practices.
- 1:10:51Speaker 1: It's called GLP. And so they conducted non-clinical mouse studies
- 1:10:58Speaker 1: of this vaccination using nine to 10 mice, This is
- 1:11:02Speaker 1: before their 40,000 or 2,900 people study. They had these
- 1:11:09Speaker 1: nine to 10 animals per group. And what possibly could
- 1:11:15Speaker 1: you gain from nine to 10 mice? Don't know. But
- 1:11:23Speaker 1: that study, the government was like, Oh, that's not remotely
- 1:11:27Speaker 1: large enough because that's nine to 10 mice and, and,
- 1:11:31Speaker 1: You also didn't follow good laboratory practices, which could mean
- 1:11:36Speaker 1: that their cages were dirty or things were contaminated or whatever.
- 1:11:42Speaker 1: So they didn't follow study protocols in this either. But FDA,
- 1:11:49Speaker 1: goddamn you, they approved it anyway, right? So not only
- 1:11:54Speaker 1: did they do that, they did another study that was
- 1:11:57Speaker 1: with weasels. or ferrets, not weasels. So I guess for
- 1:12:04Speaker 1: whatever reason, studies on ferrets are more accurate when it
- 1:12:12Speaker 1: comes to respiratory viruses than mice studies, because I guess
- 1:12:19Speaker 1: ferrets' respiratory response is more like human response than a mouse.
- 1:12:25Speaker 1: I didn't know that, never heard of that before, but
- 1:12:28Speaker 1: it's true. So they also did a study with ferrets
- 1:12:33Speaker 1: and whatever. But again, there were issues with the study and,
- 1:12:38Speaker 1: you know, all of these things. And so study parameters
- 1:12:42Speaker 1: either broken, not held to cleanliness standards or, you know, whatever,
- 1:12:48Speaker 1: or they're changed in the middle of a thing to
- 1:12:52Speaker 1: show better outcomes. Hence why I said earlier, lying with statistics.
- 1:13:01Speaker 2: So I think because I'm fact checking myself really quickly,
- 1:13:08Speaker 2: I'm pretty sure that they did the RSV trial before
- 1:13:13Speaker 2: they rolled that out. And there was this study with
- 1:13:18Speaker 2: mice that apparently the mice did very, very poor and
- 1:13:21Speaker 2: majority of them did not make it. Again, don't quote me.
- 1:13:24Speaker 2: I'm trying to look it up. But and this was
- 1:13:26Speaker 2: known and they still rolled out the RSV vaccine, still
- 1:13:29Speaker 2: push it on pregnant women, still say it's safe and effective. So,
- 1:13:33Speaker 2: you know, again, it's just another bullshit tactic. It's a
- 1:13:37Speaker 2: poor ethical standard that these so-called, you know, trials put on.
- 1:13:45Speaker 2: get away with basically, you know, half-assed information, manipulated data,
- 1:13:49Speaker 2: and then get to turn around and say, oh, well,
- 1:13:51Speaker 2: it's safe and effective. So much so that we're going
- 1:13:53Speaker 2: to recommend and push this on some of the most
- 1:13:57Speaker 2: vulnerable populations.
- 1:13:58Speaker 1: Right, 100%.
- 1:13:58Speaker 2: And you know what? If something happens because of the
- 1:14:03Speaker 2: 1986 Act, they're 100% not liable. So you're stuck with it.
- 1:14:07Speaker 2: And that's what you have to be able to decide.
- 1:14:10Speaker 2: And again, where this mRNA technology comes from when there's
- 1:14:13Speaker 2: still so much unknown.
- 1:14:15Speaker 1: Right.
- 1:14:15Speaker 2: No air quotes. But we see it every day. We
- 1:14:18Speaker 2: see the problems.
- 1:14:20Speaker 1: And I'm going to throw this out there for anybody
- 1:14:23Speaker 1: that is interested. If you want to go look up
- 1:14:29Speaker 1: about the study yourself, you can go read the FDA's
- 1:14:34Speaker 1: briefing documents. I will give you the website happily. It's FDA.gov
- 1:14:42Speaker 1: backslash media.gov. backslash one nine four one four zero backslash download.
- 1:14:49Speaker 1: You can go read the FDA's review and what they found.
- 1:14:55Speaker 1: And like I said, you're going to see a lot
- 1:14:57Speaker 1: of the same things I did where it can't be related.
- 1:15:00Speaker 1: Couldn't be this. It's not inside the 42 risk window, blah, blah, blah.
- 1:15:05Speaker 1: I I'm not just spouting numbers. I actually went through
- 1:15:09Speaker 1: their thing. It's a hundred and 123 pages.
- 1:15:15Speaker 2: Jesus. What was that number again? So it was fda.gov
- 1:15:17Speaker 2: backslash media, backslash.
- 1:15:20Speaker 1: One nine four one four zero backslash download.
- 1:15:27Speaker 2: Yeah. I'm curious. Yeah. Because again, this is going to be,
- 1:15:31Speaker 2: this is going to be huge. I mean, so many
- 1:15:33Speaker 2: people feel as if that the flu vaccine, because it's
- 1:15:38Speaker 2: been out on the market is right. Again, say I'm
- 1:15:41Speaker 2: using air quotes safer than the COVID-19 vaccine is, And
- 1:15:44Speaker 2: now it's going to be right in line with the
- 1:15:47Speaker 2: COVID-19 vaccine because of the mRNA technology. I don't foresee
- 1:15:51Speaker 2: they're going to reinvent the wheel. They'll use the same
- 1:15:53Speaker 2: exact technology.
- 1:15:54Speaker 1: Right, 100%. And here we go.
- 1:15:56Speaker 2: It's going to be COVID 2.0 when it starts to
- 1:15:59Speaker 2: roll out. So be aware.
- 1:16:01Speaker 1: And for people to understand the reason why I keep
- 1:16:06Speaker 1: referencing the COVID vaccine is because The COVID vaccine is
- 1:16:11Speaker 1: also in a post-marketing study right now, right? Because they
- 1:16:17Speaker 1: did the emergency approval. It was rushed out. So they're
- 1:16:21Speaker 1: also still collecting data, which is exactly what they're doing
- 1:16:26Speaker 1: with this flu vaccine. So please go ahead and get it.
- 1:16:29Speaker 1: We're going to use you as guinea pigs. We don't
- 1:16:32Speaker 1: know the safety or efficacy. We don't know any long-term effects.
- 1:16:37Speaker 1: We don't know, like, any of the stuff. And like
- 1:16:39Speaker 1: I read to you in a lot of the study
- 1:16:42Speaker 1: notes from the FDA review, it was, look the other way.
- 1:16:47Speaker 1: We know these things are problems. We have Jillian Barr.
- 1:16:52Speaker 1: We have myocarditis, pericarditis. We have all of these things.
- 1:16:58Speaker 1: We have unexplained or unspecified deaths. They change the category.
- 1:17:06Speaker 1: Let me explain that a little bit better. So they
- 1:17:13Speaker 1: did a study on this, right? And so somebody broke
- 1:17:17Speaker 1: down these numbers beautifully during their study. So with their thing,
- 1:17:24Speaker 1: it was deaths at first, just deaths. And then they
- 1:17:28Speaker 1: put unexplained deaths. They expanded the category, kind of like
- 1:17:33Speaker 1: they have on other shows we've talked about where they
- 1:17:36Speaker 1: do that to encompass more stuff. like the sudden infant
- 1:17:42Speaker 1: death syndrome, and then it's called something else. Sudden unexplained
- 1:17:48Speaker 1: infant death, they changed the name. So in this, in
- 1:17:52Speaker 1: this re-study, they found that 23 deaths occurred from this
- 1:17:59Speaker 1: mRNA flu vaccine compared to nine from the regular flu vaccine.
- 1:18:05Speaker 1: That's quite a bit of difference compared From what their
- 1:18:11Speaker 1: original Moderna study stuff says and what an independent evaluator
- 1:18:18Speaker 1: found in their numbers. Again, lying with statistics and nothing
- 1:18:24Speaker 1: to see here because everything was like, oh, it's not
- 1:18:27Speaker 1: a vaccine safety signal. These things couldn't possibly be coming
- 1:18:30Speaker 1: from blah, blah, blah. Not the vaccine. It has to
- 1:18:34Speaker 1: be something else. So they know. Ahead of time, they
- 1:18:39Speaker 1: know about all of these things that they're supposed to
- 1:18:43Speaker 1: be looking at. And one of the... other thing regarding
- 1:18:52Speaker 1: this study that they did that we were talking about
- 1:18:55Speaker 1: with this flu vaccine, they ran the trial during one
- 1:19:03Speaker 1: flu season, 24 and 25 in Northern California. the Northern
- 1:19:09Speaker 1: hemisphere flu season. So it was only one run for
- 1:19:14Speaker 1: one flu season. And the FDA themselves were like, you
- 1:19:18Speaker 1: know what? Should have probably been at least two or
- 1:19:22Speaker 1: more too. Cause like we talked about different strands of
- 1:19:26Speaker 1: flu come through whatever. So their study again, hinges on
- 1:19:31Speaker 1: just data collection from one flu season. and a very
- 1:19:37Speaker 1: small percentage of population. If you ask me, if, you know,
- 1:19:42Speaker 1: if you did a 40,000 people study in a place
- 1:19:46Speaker 1: where there were 56,000 people, that might be one thing.
- 1:19:50Speaker 1: But when you're over 300 million people and you're looking
- 1:19:55Speaker 1: at 40,000, those numbers are very small or the 2,900
- 1:19:58Speaker 1: number of people.
- 1:20:02Speaker 2: It really makes you wonder. And again, just kind of
- 1:20:05Speaker 2: goes to our point that it's not good data and
- 1:20:11Speaker 2: it's not being done in a way that, um, would
- 1:20:14Speaker 2: give you the most solid informed consent. And that should
- 1:20:18Speaker 2: really concern you. Like of all the things that we've
- 1:20:20Speaker 2: said in this episode of all the things that we're
- 1:20:21Speaker 2: referencing at the most basic level, you have two different
- 1:20:26Speaker 2: studies that are basically, you know, um, not following the guidelines, right.
- 1:20:31Speaker 2: Going around, cutting corners, um, Right. Moving the goalposts, having
- 1:20:35Speaker 2: this magic math, you know, all these things that just
- 1:20:38Speaker 2: right there should give you the red flags enough to
- 1:20:42Speaker 2: pause and say, you know, this probably isn't the best
- 1:20:47Speaker 2: for what we want to be able to make a
- 1:20:49Speaker 2: good decision. If this is the right way to go. Right.
- 1:20:52Speaker 2: Get a flu vaccine. And then just, again, know that,
- 1:20:55Speaker 2: you know, the main study is. still is giving them
- 1:20:58Speaker 2: a grace period for a couple more years to be
- 1:21:01Speaker 2: able to see how well their product is doing. And
- 1:21:04Speaker 2: in the meantime, anyone that gets that is going to
- 1:21:07Speaker 2: be part of that when they're given it and their
- 1:21:10Speaker 2: physician or pharmacist is going to document that they've given
- 1:21:14Speaker 2: you this mRNA technology. So, you know, be very, very weary,
- 1:21:17Speaker 2: be very clear that mRNA technology per a simple Google
- 1:21:21Speaker 2: search is designed to rapidly reproduce and And once it starts,
- 1:21:27Speaker 2: it does not stop. And this is why so many
- 1:21:30Speaker 2: people have had these health issues because of it. So,
- 1:21:33Speaker 2: you know.
- 1:21:34Speaker 1: And I'm just going to throw this out there. And
- 1:21:38Speaker 1: I know I've talked about this on a previous, several
- 1:21:41Speaker 1: previous episodes. But I'm wondering, using my critical thinking brain,
- 1:21:47Speaker 1: if the reason why this keeps replicating is if it
- 1:21:51Speaker 1: shuts off the methylation process in the body, which is
- 1:21:55Speaker 1: your on-off switch, I wonder if it permanently shuts that
- 1:22:00Speaker 1: off so that it just continues and there's nothing to
- 1:22:04Speaker 1: stop it.
- 1:22:05Speaker 2: Right. It's a great question. And I think something else
- 1:22:08Speaker 2: that is confusing to a lot of people is that
- 1:22:10Speaker 2: there's people that say, oh, I've had numerous COVID shots
- 1:22:12Speaker 2: and I've had no problems yet. Or I don't have
- 1:22:17Speaker 2: any issues and I've only gotten one. And then there's
- 1:22:20Speaker 2: some people who just got one and who literally died
- 1:22:23Speaker 2: a few days later. The thing is, is that for
- 1:22:26Speaker 2: some reason, when that rollout came out, there are vials
- 1:22:30Speaker 2: that didn't necessarily have the same amount. And maybe the
- 1:22:35Speaker 2: way that they were drawn up, because when I worked
- 1:22:37Speaker 2: at the hospital, I think you could get four or
- 1:22:39Speaker 2: five doses out of one vial, which is what was
- 1:22:41Speaker 2: happening with the pharmacist. So who's to say, I'm not blaming,
- 1:22:44Speaker 2: but who's to say that it was drawn correctly, that
- 1:22:46Speaker 2: maybe you had a little more, a little less. Maybe
- 1:22:49Speaker 2: some of them were a weaker vial. So again, you
- 1:22:54Speaker 2: don't know. And it's something that's being given. And there's
- 1:22:58Speaker 2: no manufacturer liability. Again, that means that there is no
- 1:23:03Speaker 2: one liable for you if you are harmed by this.
- 1:23:06Speaker 2: And so that is possibly why the mRNA replicates the
- 1:23:11Speaker 2: way it does in some, because they just had some
- 1:23:14Speaker 2: batches that they call hot lots. This can be the
- 1:23:17Speaker 2: same thing for the flu, the mRNA flu vaccine, you know,
- 1:23:20Speaker 2: they could come out where you start to see these vials,
- 1:23:24Speaker 2: potentially these certain batches have more of a problem reported,
- 1:23:28Speaker 2: than others. And so I think it's definitely something we
- 1:23:31Speaker 2: need to continue to watch very closely. We need to
- 1:23:33Speaker 2: keep talking about it. We need to make sure people
- 1:23:35Speaker 2: understand that this is going to be like a COVID 2.0
- 1:23:39Speaker 2: and that, you know, the studies are not good and,
- 1:23:41Speaker 2: you know, where it may be on pause right now
- 1:23:43Speaker 2: and where they're going to keep telling you it's only
- 1:23:45Speaker 2: for the older age groups. Just please remember it started
- 1:23:49Speaker 2: like that during COVID as well. where they targeted the
- 1:23:52Speaker 2: elderly and then they quickly came out and said, Oh no, no, no.
- 1:23:55Speaker 2: Now we're going to start hitting the middle age. Now
- 1:23:57Speaker 2: we're going to start hitting the kids, the adolescents. Now
- 1:23:59Speaker 2: we're coming for your infants and you know, toddlers and
- 1:24:03Speaker 2: it just exploded. So I wouldn't put it past them.
- 1:24:06Speaker 2: And I think that we need to be hypervigilant when
- 1:24:08Speaker 2: it comes to that because it's, it's coming full steam ahead.
- 1:24:12Speaker 1: Well, and I want to make this clear because I'm
- 1:24:16Speaker 1: talking about a weakened batch of in a vial compared
- 1:24:22Speaker 1: to a different batch number lot number that happens we
- 1:24:27Speaker 1: you had briefly discussed this with me before was the
- 1:24:31Speaker 1: overfilling of the mmr vaccines they do do that because
- 1:24:38Speaker 1: if the vaccines break down which was what the case
- 1:24:41Speaker 1: was with the mmr stuff um they have to make
- 1:24:46Speaker 1: it to a certain strength so that when it is
- 1:24:49Speaker 1: looked at by the FDA that it's still strong that
- 1:24:53Speaker 1: it hasn't broken down so is that an issue with
- 1:24:58Speaker 1: these has that been an issue with other vaccinations I'm
- 1:25:02Speaker 1: going to say yes so and were some batches during
- 1:25:08Speaker 1: the COVID stuff designed to be not as harmful as
- 1:25:14Speaker 1: the other ones because there's a lot of talk about that.
- 1:25:17Speaker 1: A lot of people independently have verified what's in these
- 1:25:22Speaker 1: vials and whatever. So I'm sure that's going to happen
- 1:25:29Speaker 1: once this actually hits the market and for use. But yeah,
- 1:25:35Speaker 1: I can see that being an issue with those two
- 1:25:38Speaker 1: where some of them are not as potent because they
- 1:25:41Speaker 1: even did that during their own study. You know what
- 1:25:45Speaker 1: I mean? They're not using the standard protocol of the
- 1:25:49Speaker 1: dosage you're supposed to be using, they used a weaker
- 1:25:52Speaker 1: dosage to make it look better in the study. And
- 1:25:56Speaker 1: then they changed in the middle of the study to
- 1:25:59Speaker 1: something stronger because the FDA was like, no, we're not
- 1:26:03Speaker 1: going to approve this.
- 1:26:05Speaker 2: And a very, very big point to make is that
- 1:26:09Speaker 2: They don't hide this from any of us. Right. People
- 1:26:12Speaker 2: people tend to get like all woo woo and like, oh,
- 1:26:15Speaker 2: you guys are not credible. And you're again, the conspiracy
- 1:26:18Speaker 2: theory and all this read. Go educate yourself. The thing
- 1:26:23Speaker 2: that is just the most mind blowing is that we
- 1:26:26Speaker 2: are taught one way, but the actual answers are in words.
- 1:26:31Speaker 2: depth into the literature, into the ingredients, the manufacturer's insert. Right.
- 1:26:37Speaker 2: It's all there and it's really humbling and it's really
- 1:26:40Speaker 2: disheartening because we're You know, I think if more people
- 1:26:42Speaker 2: actually took it seriously and did their own research, they
- 1:26:45Speaker 2: wouldn't look at us like we're crazy or like we're
- 1:26:46Speaker 2: trying to tell them, you know, that we're practicing outside
- 1:26:49Speaker 2: of our scope and telling you not to do something.
- 1:26:52Speaker 2: It's really, we want you to be informed and we
- 1:26:54Speaker 2: want you to know that you're being lied to. And
- 1:26:56Speaker 2: the reason why we know that is because we've done
- 1:26:58Speaker 2: our research and it's right there from the actual manufacturers
- 1:27:01Speaker 2: in the trials. They're telling you they're not doing stuff.
- 1:27:04Speaker 2: They're telling you that they're not following the criteria. They're
- 1:27:06Speaker 2: actually telling you.
- 1:27:07Speaker 1: The federal government's telling you. Exactly.
- 1:27:11Speaker 2: And the products are showing that they are not effective
- 1:27:14Speaker 2: or they cause harm or, you know, it's all there.
- 1:27:17Speaker 2: And so people need to understand that it's right in
- 1:27:21Speaker 2: front of you. If you just take time to do
- 1:27:23Speaker 2: your own research and understand what you're looking at, you know,
- 1:27:26Speaker 2: even sometimes the jargon can be a little off. The
- 1:27:28Speaker 2: basic information is there. It will tell you what you
- 1:27:33Speaker 2: are going to be up against and what this looks
- 1:27:35Speaker 2: like for people in their trials. Even the crappy trials
- 1:27:38Speaker 2: will show you not good things. And they'll still tell you, Oh,
- 1:27:43Speaker 2: what's your risk versus benefit. So I just think it's
- 1:27:45Speaker 2: so important. People understand none of this is hidden. It's
- 1:27:49Speaker 2: all there. You just have to take time to look
- 1:27:50Speaker 2: for it and be able to just have an open mind,
- 1:27:53Speaker 2: just read it. And again, if you read it and
- 1:27:55Speaker 2: you feel comfortable, and this is something that you think
- 1:27:57Speaker 2: makes the, is more beneficial to you than not, then
- 1:28:00Speaker 2: so be it, but it's not for the majority. And
- 1:28:03Speaker 2: here's why all the reasons we listed in the middle
- 1:28:06Speaker 2: of this podcast. Right.
- 1:28:08Speaker 1: And you know, um, we're basically a show for informed consent.
- 1:28:13Speaker 1: We want you to know the truth behind everything. It's
- 1:28:17Speaker 1: your responsibility to make a good informed decision on your
- 1:28:24Speaker 1: body and what you want to do. And if you
- 1:28:26Speaker 1: want to go get it by all means have at it,
- 1:28:30Speaker 1: but it should be something that's by choice and never
- 1:28:34Speaker 1: by force. Um, and so we just, we do these
- 1:28:37Speaker 1: shows because we want you guys to Have fun. an
- 1:28:40Speaker 1: education outside of what you're going to get in the
- 1:28:43Speaker 1: mainstream media narrative. And when I tell you that FDA
- 1:28:50Speaker 1: evaluation of this study was 123 pages long, I cannot
- 1:28:55Speaker 1: tell you, it's taken me like two weeks to put
- 1:28:58Speaker 1: this together. because I was reading until I thought my
- 1:29:03Speaker 1: eyeballs were going to fall out of my face. So,
- 1:29:06Speaker 1: you know, if you want to go read just the
- 1:29:09Speaker 1: FDA review, you're more than welcome to. If you want
- 1:29:12Speaker 1: to go read the actual Moderna study, you're more than
- 1:29:16Speaker 1: welcome to go do that as well. But I'm probably
- 1:29:20Speaker 1: guessing you're not going to want to.
- 1:29:22Speaker 2: Well, and we encourage it. Like I said, there's no
- 1:29:25Speaker 2: hidden agenda here. I know we are obviously swaying towards
- 1:29:29Speaker 2: not wanting anything to do with it and very anti,
- 1:29:31Speaker 2: but I guess if you actually listen to what we're saying,
- 1:29:34Speaker 2: you would hear why, right? It's a common trend. It's
- 1:29:37Speaker 2: becoming a trend. It's, you know, watching people become harmed
- 1:29:40Speaker 2: and die as someone who's a vaccine injury advocate, you know,
- 1:29:46Speaker 2: with your own eyes, like I'm tired, I'm emotionally tired. I'm,
- 1:29:49Speaker 2: I'm sad. My heart is consistently broken. People are like, Oh,
- 1:29:53Speaker 2: you're so full of shit. You know? And it's like,
- 1:29:54Speaker 2: it's not just the COVID vaccine. It's children that have
- 1:29:56Speaker 2: been harmed and, you know, parents that have to take
- 1:29:59Speaker 2: care of them for the rest of their life, hoping
- 1:30:01Speaker 2: that they outlive their children because they're so afraid of,
- 1:30:05Speaker 2: after they thought they did the right thing by giving
- 1:30:08Speaker 2: them vaccines and then their children horribly regressing and having
- 1:30:11Speaker 2: horrible things happen to them if they even lived. And
- 1:30:14Speaker 2: then now seeing adults, because they have an adult vaccine schedule,
- 1:30:17Speaker 2: getting these and being told You have to have it
- 1:30:20Speaker 2: to do X, Y, and Z to be in society.
- 1:30:23Speaker 2: And then having problems happen and then no one else
- 1:30:27Speaker 2: is liable. The healthcare system consistently gaslights these people. They
- 1:30:31Speaker 2: don't recognize them as vaccine injuries. They don't want to
- 1:30:34Speaker 2: do it. They don't want to put the label on it.
- 1:30:35Speaker 2: And if you do have the label, because there are
- 1:30:38Speaker 2: some brave physicians who have done it, the amount of
- 1:30:42Speaker 2: stigma and the discrimination that I have witnessed go against
- 1:30:47Speaker 2: these people who are injured. is absolutely abhorrent that in
- 1:30:51Speaker 2: healthcare where we took an oath to do no harm
- 1:30:53Speaker 2: and we have such an ego and bias towards these
- 1:30:56Speaker 2: people who are just hurting and just want some sort
- 1:30:59Speaker 2: of quality of life. So that is why these topics
- 1:31:02Speaker 2: are so passionate for us. And, you know, for me,
- 1:31:06Speaker 2: because I see it every day and, and it's like,
- 1:31:08Speaker 2: you can't stop it because the damage is already done.
- 1:31:12Speaker 2: And again, this is going to affect fertility, you know,
- 1:31:15Speaker 2: all these women that were vaccinated while they were pregnant,
- 1:31:19Speaker 2: then these babies coming out of the womb being immediately injected,
- 1:31:23Speaker 2: you know, COVID-19 vaccines are on. the childhood vaccination schedule
- 1:31:28Speaker 2: as recommended, not, you know, so they're making changes, but
- 1:31:31Speaker 2: 9 million children already had it in the United States
- 1:31:37Speaker 2: and they are pushed to get the flu vaccine. So
- 1:31:39Speaker 2: this is a real concern and why people need to
- 1:31:41Speaker 2: understand that, you know, if you are not affected directly,
- 1:31:47Speaker 2: you most likely know someone who has been And that's
- 1:31:52Speaker 2: just enough for you to want to question it is
- 1:31:54Speaker 2: why we do these informational podcasts is to question it
- 1:31:59Speaker 2: and have you want to dive deeper. Right.
- 1:32:02Speaker 1: And, you know, it doesn't always have to be like
- 1:32:10Speaker 1: something happened from, you know, this vaccine or this medication
- 1:32:15Speaker 1: or whatever. There's a lot of factors that play into everything,
- 1:32:19Speaker 1: but every human being is different. So even if you
- 1:32:23Speaker 1: got that weakened dose of the COVID shot or whatever
- 1:32:28Speaker 1: and nothing happened to you, that's great for you. You're
- 1:32:31Speaker 1: a different person. Each one of us are individual. So
- 1:32:35Speaker 1: this should never, ever be a blanket thing across the
- 1:32:39Speaker 1: board where everybody's required to get it because everybody's body
- 1:32:44Speaker 1: is different and responds differently.
- 1:32:47Speaker 2: No, it's true. And I think people get so wrapped
- 1:32:50Speaker 2: up into, oh, it's not going to happen to me
- 1:32:52Speaker 2: or it doesn't affect me. And I pray that it
- 1:32:55Speaker 2: never does. I don't wish any of this on my
- 1:32:57Speaker 2: worst enemy when you see what it does. And so, again,
- 1:33:01Speaker 2: it's hard to swallow being in the medical field for
- 1:33:04Speaker 2: as long as I have that this could be something
- 1:33:07Speaker 2: intentionally done. Take that information as you want. And to
- 1:33:11Speaker 2: consistently see the harm and these repeat customers being made.
- 1:33:15Speaker 2: because they're being hurt by big pharma as a whole.
- 1:33:19Speaker 2: It's not just vaccines, it goes beyond that. And so again,
- 1:33:22Speaker 2: it's really important that people hear what information is being provided.
- 1:33:27Speaker 2: Janet does a fantastic job of researching, bringing facts to
- 1:33:31Speaker 2: the table, explaining it super well. And at a level
- 1:33:35Speaker 2: that I think majority of people can understand. And if
- 1:33:37Speaker 2: you actually take some of the information and just kind of,
- 1:33:40Speaker 2: you know, do some of your own research, I'm telling you,
- 1:33:43Speaker 2: once you are awakened to what you are hearing, you
- 1:33:46Speaker 2: will never go back because then you start to go,
- 1:33:49Speaker 2: what we say is down the rabbit hole. And it
- 1:33:51Speaker 2: just shows you the bias, the hand of big pharma
- 1:33:56Speaker 2: and what this looks like, that it is essentially profit
- 1:33:59Speaker 2: over patient, your health, is, I mean, they coerce you
- 1:34:03Speaker 2: to do things. And your health is literally at the
- 1:34:05Speaker 2: hands of people who are not liable. And if so, very,
- 1:34:11Speaker 2: very hard to prove. That's a big deal.
- 1:34:14Speaker 1: Well, and here's something that I'm going to emphasize again
- 1:34:19Speaker 1: for people who didn't hear me talk about this before. Okay,
- 1:34:24Speaker 1: so if I... worked for the FDA and this paperwork
- 1:34:29Speaker 1: came across my desk, I would throw it in the
- 1:34:32Speaker 1: garbage can. I'd be like, absolutely not. You didn't stick
- 1:34:35Speaker 1: to the trial. You screwed up the parameters. You did
- 1:34:39Speaker 1: all this stuff. But here's what you people need to understand.
- 1:34:44Speaker 1: Almost 85%, which is a huge, huge number of previous
- 1:34:48Speaker 1: FDA directors or bigwigs or people that work in approval
- 1:35:02Speaker 1: go in the revolving door to big pharma to get
- 1:35:07Speaker 1: a CEO or executive job or vice versa. They come
- 1:35:13Speaker 1: from the pharma side and then they come into the
- 1:35:17Speaker 1: FDA to work on the approval side. So we're grazing
- 1:35:23Speaker 1: palms both ways in, in this system that we live in.
- 1:35:29Speaker 1: And the government gets shit tons of money from big pharma.
- 1:35:34Speaker 1: That is why things like this get approved, even though
- 1:35:39Speaker 1: it's faulty. The mouse study was do was, was corrupt.
- 1:35:44Speaker 1: It wasn't good laboratory practices that study of 2,900 people,
- 1:35:50Speaker 1: a study of 40,000 where they're changing their parameters. This,
- 1:35:54Speaker 1: if it were me, would just absolutely no. I wouldn't
- 1:35:58Speaker 1: consider it a second time. I would rubber stamp this. Failed.
- 1:36:03Speaker 1: But the government lets it go because, like I said,
- 1:36:07Speaker 1: a huge number of our government go on to work
- 1:36:11Speaker 1: in pharma or pharma comes to work in their government approvals.
- 1:36:16Speaker 2: And that is huge, right? Because you want to talk
- 1:36:18Speaker 2: about a bias. But one of the things, because I
- 1:36:20Speaker 2: know we're at time here, that I just want people
- 1:36:23Speaker 2: to understand why we question, when I say the three-letter agencies,
- 1:36:27Speaker 2: the CDC, the FDA, you know, all of that, NIH,
- 1:36:30Speaker 2: you know, is since early 2000, a simple Google search,
- 1:36:36Speaker 2: over 100,000 individual recalls have been done that were previously
- 1:36:43Speaker 2: FDA approved, which include food, drugs, medical devices, and cosmetics.
- 1:36:51Speaker 2: Over 100,000 recalls. That means that the FDA put their
- 1:36:54Speaker 2: stamp of approval, said that these products were safe, they
- 1:36:58Speaker 2: were effective, they were tried, and they pushed them out
- 1:37:00Speaker 2: onto the market, were coming back as causing harm or
- 1:37:06Speaker 2: death and had to be recalled and and basically said, oh,
- 1:37:10Speaker 2: we made a mistake. We got to pull this, you know,
- 1:37:13Speaker 2: immediately get rid of it. Stop using it. This has
- 1:37:16Speaker 2: caused harm and death. So this is, again, why some
- 1:37:20Speaker 2: of us are very weary when these three-letter agencies come
- 1:37:23Speaker 2: out and say, oh, it's no problem. Like, you know,
- 1:37:24Speaker 2: when the government tells you it's okay, we're the government,
- 1:37:27Speaker 2: we're here to help you, run like hell the other way.
- 1:37:30Speaker 2: This is a prime example. Over 100,000 individual recalls by
- 1:37:34Speaker 2: the FDA since early 2000 on a wide variety of
- 1:37:37Speaker 2: products That is why you should question everything.
- 1:37:40Speaker 1: That used to be part of my job at the
- 1:37:43Speaker 1: teaching facility. It was to monitor things that were pulled
- 1:37:47Speaker 1: off or recalled, changed formulation, whatever. Yeah. So very passionate
- 1:37:54Speaker 1: about that whole thing. So my darling, thank you so
- 1:37:59Speaker 1: much for your time and your energy and your brain cells.
- 1:38:04Speaker 1: I appreciate you so much. where can the lovely ladies
- 1:38:09Speaker 1: and gentlemen find you at?
- 1:38:12Speaker 2: Thank you. It was a great episode. So first, I
- 1:38:15Speaker 2: am a Friday Q & A nurse on the Nurses Report,
- 1:38:18Speaker 2: which is on americaoutloud.news. I also co-host with Dan the
- 1:38:23Speaker 2: Messenger on the Frontline Messengers podcast. And then I'm really
- 1:38:28Speaker 2: active on Instagram, on hold. So H-O-L-D underscore. And then
- 1:38:33Speaker 2: it's one word, the line C-L-N-C, where I do a
- 1:38:37Speaker 2: lot of education and information and talk about things we're
- 1:38:40Speaker 2: doing on a local and state level in Florida, as
- 1:38:42Speaker 2: well as how we're helping the vaccine injured and bereaved.
- 1:38:45Speaker 2: So thank you.
- 1:38:47Speaker 1: Which is very important work that you do. And that
- 1:38:51Speaker 1: is why we're very passionate, both of us, about giving
- 1:38:55Speaker 1: you information about stuff, because I have dealt with a
- 1:39:00Speaker 1: lot of vaccine-injured people as well, my daughter being one
- 1:39:03Speaker 1: of them. So, yeah, this topic, like, Uber, it's not
- 1:39:09Speaker 1: for both of us. So, for me and for the beautiful, lovely,
- 1:39:14Speaker 1: and talented Nurse Nicole, thank you so much for tuning in.
- 1:39:19Speaker 1: And we will see you next time.